etoposide has been researched along with Leukemia in 346 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 80 (23.12) | 18.7374 |
1990's | 122 (35.26) | 18.2507 |
2000's | 100 (28.90) | 29.6817 |
2010's | 41 (11.85) | 24.3611 |
2020's | 3 (0.87) | 2.80 |
Authors | Studies |
---|---|
Barrows, LR; Chen, AY; LaVoie, EJ; Liu, LF; McQueen, CA; Meegalla, SK; Stevens, GJ; Yu, C | 1 |
Chen, JY; Cheng, KF; Ding, J; Meng, LH; Qin, GW; Yu, BW; Zhou, TX | 1 |
Atwal, M; Austin, CA; Bartoli, A; Lee, KC; Mariani, A; Rodriguez, R | 1 |
Dezhenkova, LG; Kalinina, AA; Kaluzhny, DN; Kubbutat, M; Luzikov, YN; Pommier, Y; Preobrazhenskaya, MN; Romanenko, VI; Schols, D; Shchekotikhin, AE; Shtil, AA; Tatarskiy, VV; Treshalin, MI; Treshalina, HM; Tsvetkov, VB; Volodina, YL | 1 |
Chen, F; Chen, Y; Lin, Y; Wang, J; Zhang, L; Zhang, Z | 1 |
Cheung, NV; Davenport, JW; Felix, CA; Gregory, BD; Li, MM; Rappaport, EF; Slater, DJ; Yu, X | 1 |
Cross, NA; Jordan-Mahy, N; Le Maitre, CL; Mahbub, AA | 1 |
Carvajal-Moreno, J; Elton, TS; Hernandez, VA; Pietrzak, M; Wang, X; Yalowich, JC | 1 |
Garten, A; Grohmann, T; Kiess, W; Penke, M; Petzold-Quinque, S; Richter, S; Schuster, S | 1 |
Aladjidi, N; Auperin, A; Couec, ML; Gandemer, V; Haouy, S; Jourdain, A; Lambliotte, A; Landman-Parker, J; Leblanc, T; Michon, J; Minard-Colin, V; Patte, C; Plat, G; Rigaud, C | 1 |
Chen, S; Chen, Y; Rao, Q; Tang, K; Tian, Z; Wang, J; Wang, JY; Wang, M; Xing, H; Yu, P | 1 |
Ahmad, SF; Attia, SM; Bakheet, SA; El Sayed, el SM; Harisa, GI; Mansour, AM | 1 |
Baradaran, B; Esfehani, A; Karami, H; Sakhinia, E; Sakhinia, M | 1 |
Byl, JA; Deweese, JE; Mercer, SL; Osheroff, N; Smith, NA | 1 |
Dong, B; Huang, H; Qu, L; Weng, H; Zhao, P; Zhou, H | 1 |
Shibayama, Y; Sugawara, M; Takada, K; Takekuma, Y; Tazawa, Y; Usukubo, I | 1 |
Hasinoff, BB; Patel, D; Wu, X; Yadav, AA; Yalowich, JC | 1 |
Beck, J; Burmeister, T; Dengler, J; Döhner, H; Domanska-Czyz, K; Dührsen, U; Fietkau, R; Gökbuget, N; Hertenstein, B; Hiddemann, W; Hoelzer, D; Horst, HA; Hüttmann, A; Kneba, M; Reichle, A; Rieder, H; Schaich, M; Schmidt-Wolf, IG; Schwartz, S; Serve, H; Spiekermann, K; Thiel, E; Viardot, A; Walewski, J | 1 |
Lehman, CE; Pierce, LC; Thys, RG; Wang, YH | 1 |
Mizutani, S; Nanya, M; Sato, M; Takagi, M; Tanimoto, K; Tozuka, M | 1 |
Aquino, V; Duerst, R; Graham, M; Moore, T; Morris, C; Morris, J; Neudorf, S; Olsson, B; Rudebeck, M; Shah, AJ | 1 |
Gerber, JM; Grunwald, MR; Induru, R; McDonnell, MH | 1 |
Chen, Z; Hu, S | 1 |
Aqaqe, N; Biechonski, S; Elad, D; Gourevich, D; Grisaru, D; Jaffa, AJ; Milyavsky, M; Olender, L; Rall, M; Raz, Y; Trakhtenbrot, L; Wiesmuller, L; Yassin, M; Zipin-Roitman, A | 1 |
Al Malki, MM; Aldoss, I; Ali, H; Aribi, A; Farol, L; Forman, SJ; Karanes, C; Khaled, S; Liu, A; Marcucci, G; Nakamura, R; O'Donnell, M; Palmer, J; Parker, P; Pawlowska, A; Pullarkat, V; Radany, E; Rosenthal, J; Sahebi, F; Salhotra, A; Sanchez, JF; Schultheiss, T; Snyder, D; Spielberger, R; Stein, A; Thomas, SH; Tsai, NC; Wong, J | 1 |
Accordino, MK; Hershman, DL; Hillyer, GC; Neugut, AI; Vasan, S; Wright, JD | 1 |
Cheung, NK; Jhanwar, SC; Kramer, K; Kushner, BH; Modak, S; Qin, LX; Yataghena, K | 1 |
Kamijo, T; Koike, K; Nakazawa, Y; Sakashita, K; Shikama, N; Shiohara, M; Tanaka, M; Yanagisawa, R | 1 |
Barretto, NN; Bennett, CA; Hemenway, CS; Winters, AC | 1 |
Chen, GQ; Duan, XF; Wen, DH; Zhao, M | 1 |
Diao, S; Liu, H; Rao, Q; Wang, J; Wang, M; Xing, H; Zhang, X | 1 |
Chen, GQ; Huang, Y; Wang, LS; Yu, Y; Yuan, TT; Zhou, CX; Zhuang, HY | 1 |
Hou, KZ; Liu, YP; Qu, XJ; Teng, YE; Yang, XH; Zhang, JD; Zhang, Y | 1 |
Chen, GQ; Cheng, JK; Duan, XF; Liu, W; Lu, Y; Zhang, B; Zhao, M; Zhao, XY | 1 |
Blasiak, J; Poplawski, T | 1 |
Abichandani, R; Barry, E; Carroll, WL; Chu, R; Cooper, T; Gaynon, P; Hijiya, N; Jeha, S; Kadota, R; Rytting, M; Shen, V; Silverman, L; Steinherz, P; Thomson, B | 1 |
Chen, ZC; Li, L; Li, QB; Xia, LH; You, Y; Zou, P | 1 |
Akutsu, M; Furukawa, Y; Izumi, T; Kano, Y; Mano, H; Miyawaki, S; Tanaka, M; Tsunoda, S; Yazawa, Y | 1 |
Grigg, AP; Hoyt, R; Ritchie, DS; Szer, J; Wirth, A | 1 |
Carlo-Stella, C; Delia, D; Drago, C; Lambertenghi Deliliers, G; Lecis, D; Manzoni, L; Onida, F; Polli, E; Scavullo, C; Seneci, P; Servida, F | 1 |
Asano, S; Funayama, K; Murai, F; Nomura, H; Shimane, M | 1 |
DeRyckere, D; Gore, L; Macy, ME | 1 |
Hara, T; Kanemura, N; Kasahara, S; Kitagawa, J; Moriwaki, H; Shimizu, M; Tsurumi, H | 1 |
Alvarnas, JC; Dagis, AC; Forman, SJ; Nademanee, AP; O'Donnell, MR; Parker, PM; Pullarkat, VA; Snyder, DS; Spielberger, RT; Stein, AS; Synold, TW; Thomas, SH; Tsirunyan, A; Wong, JY | 1 |
Andresen, S; Avalos, B; Bolwell, BJ; Copelan, E; Dean, R; Devine, S; Elder, P; Kalaycio, M; Mahindra, A; Pohlman, B; Rybicki, L; Sobecks, R; Sweetenham, J; Tench, S | 1 |
Belinka, BA; Gupta, A; Kachlany, SC; Le, A | 1 |
Bertrand, J; Bonnevialle, P; Bourogaa, E; Demur, C; Despeaux, M; Gallay, N; Joly, S; Louache, F; Maguer-Satta, V; Payrastre, B; Racaud-Sultan, C; Vergnolle, N | 1 |
Shigematsu, A | 1 |
Delalande, F; Domon-Dell, C; Duluc, I; Freund, JN; Gross, I; Martin, E; Renouf, B; Saandi, T; Soret, C; Vanier, M | 1 |
Gaynon, P; Lindsay, H | 1 |
Anderson, DJ; Belmont, LD; Bouillet, P; Campbell, KJ; Cory, S; Fairlie, WD; Glaser, SP; Huang, DC; Khaw, SL; Lee, EF; Ludlam, MJ; Mérino, D; Phipson, B; Robati, M; Roberts, AW; Vandenberg, CJ; Wong, C; Yue, P | 1 |
Braess, J; Holdenrieder, S; Kolligs, FT; Manukyan, D; Stieber, P | 1 |
Jasek, E; Jasinska, M; Jurkowska, H; Lis, GJ; Litwin, JA | 1 |
Matsumura, K; Sugawara, M; Takekuma, Y; Tazawa, Y | 1 |
Austin, CA; Cowell, IG | 1 |
Ahmed, AB; Bruserud, O; Hatfield, KJ; Kittang, AO; Reikvam, H; Sjo, M; Tvedt, TH | 1 |
Mizutani, S; Porter, AC; Sato, M; Shimizu, T; Takagi, M; Tamaichi, H | 1 |
Braylan, R; Chen, SF; Fieniewicz, KJ; Gomez, SP; Kahn, S; Leather, H; Lynch, J; Mainwaring, MG; May, WS; Moreb, J; Reddy, V; Rimsza, LM; Rowe, TC; Weeks, FW; Wingard, JR | 1 |
Joel, SP; Liu, WM; Oakley, PR | 1 |
Panetta, JC; Pui, CH; Relling, MV; Wilkinson, M | 1 |
Balduzzi, A; Biondi, A; Bonanomi, S; Dassi, M; Gaipa, G; Perseghin, P; Rovelli, A; Uderzo, C | 1 |
Grigg, AP; Ritchie, DS; Roberts, AW; Shuttleworth, P; Szer, J | 1 |
Allan, WP; Kroll, DJ; Kurz, EU; Leader, KB; Sampey, BP; Wilson, SE; Yalowich, JC | 1 |
Gore, SD; Malek, SN | 1 |
Grzanka, A; Grzanka, D | 1 |
Bayle, C; Bernheim, A; Cayuela, JM; Chompret, A; de Vathaire, F; Hill, C; Lacour, B; Le Deley, MC; Leblanc, T; Raquin, MA; Shamsaldin, A; Sommelet, D; Vassal, G | 1 |
Austin, RC; Baumeister, P; Kaufman, RJ; Lee, AS; Mao, C; Reddy, RK | 1 |
Abe, A; Emi, N; Kanbe, E; Kawabe, T; Saito, H; Towatari, M | 1 |
Joel, SP; Liu, WM | 1 |
Kato, K; Kojima, S; Kudo, K; Matsuyama, T; Nakamoto, C; Nakamura, Y; Yoshimi, A | 1 |
Diehl, V; Dörken, B; Dühmke, E; Franklin, J; Hasenclever, D; Herrmann, R; Lathan, B; Loeffler, M; Müller-Hermelink, HK; Paulus, U; Pfreundschuh, M; Tesch, H | 1 |
Lan, Y; Shen, BF; Yang, PD; Zhang, XM | 1 |
Rikiishi, H; Sato, K; Shinohara, F; Suzuki, M; Takada, H; Taniguchi, T | 1 |
Blanco, JG; Edick, MJ; Relling, MV | 1 |
Berger, SA; Zhang, Y | 1 |
Wang, LL; Xu, CG; Zhang, MH | 1 |
Boehden, GS; Marschalek, R; Restle, A; Stocking, C; Wiesmüller, L | 1 |
Agazzi, A; Bertolini, F; Calabrese, L; Cinieri, S; Cocquio, A; Goldhirsch, A; Laszlo, D; Martinelli, G; Pruneri, G; Rabascio, C | 1 |
Astruc, J; Barret, JM; Chansard, N; Créancier, L; Duchier, C; Hill, BT; Kruczynski, A; Menon, Y; Van Hille, B | 1 |
Campiani, G; Greene, LM; Lawler, M; Ledwidge, S; Mc Gee, MM; Nacci, V; Williams, DC; Zisterer, DM | 1 |
Markman, M | 1 |
Avalos, B; Bechtel, T; Copelan, E; Elder, P; Ezzone, S; Farag, S; Hoshaw-Woodard, S; Lemeshow, S; Lin, T; Marcucci, G; Penza, S; Scholl, MD | 1 |
Abonour, R; Einhorn, LH; Houck, W; Vance, G | 1 |
Debatin, KM; Karawajew, L; Liu, J; Meyer, LH; Mohr, A; Stahnke, K | 1 |
Clotagatide, A; Denoyer, D; Dubois, F; Frere, D; Jeune, NL; Perek, N; Sabido, O | 1 |
Chang, JS; Choi, YB; Kim, CG; Kim, JW; Kim, YH; Ko, J; Kuroki, T; Lee, YH; Min, DS; Na, DS; Ohba, M; Shin, SY | 1 |
Billi, AM; Bortul, R; Cocco, L; Conte, R; Manzoli, L; Martelli, AM; Tabellini, G; Tazzari, PL | 1 |
Cataldi, A; Comani, S; Di Pietro, R; Rapino, M; Sabatini, N; Sancilio, S | 1 |
Ikarashi, Y; Imai, C; Kakihara, T; Tanaka, A; Uchiyama, M; Watanabe, A | 1 |
Chen, Q; Chen, Y; Hou, Y; Li, C; Li, X; Wang, B; Zhang, Z; Zou, P | 1 |
Beauchemin, M; Bergeron, S; Bertrand, R | 1 |
Bauer, KS; Garimella, TS; Karp, JE; Ross, DD; Tan, M; Wu, S | 1 |
Arai, A; Jin, ZH; Kurosu, T; Miura, O; Yamaguchi, M | 1 |
Magnusson, KE; Navakauskiene, R; Savickiene, J; Treigyte, G | 1 |
Seiter, K | 1 |
Hartmann, O; Le Deley, MC; Leblanc, T; Shamsaldin, A; Taïbi, A; Vassal, G | 1 |
Aksu, S; Güven, GS; Koçak, T; Ozçakar, L | 1 |
Billi, AM; Bortul, R; Cappellini, A; Conte, R; Grafone, T; Mantovani, I; Martelli, AM; Martinelli, G; Tabellini, G; Tazzari, PL | 1 |
Abella, E; Brunet, S; del Potro, E; Esteve, J; Oriol, A; Ribera, JM | 1 |
Asano, T; Fukunaga, Y; Kleinerman, ES; Zhou, Z; Zwelling, LA | 1 |
Barbier, M; Bignon, J; Boutonnat, J; Colle, PE; Faussat, AM; Marie, JP; Ronot, X; Thierry, J; Wdzieczak-Bakala, J | 1 |
Gallagher, EP; Moneypenny, CG; Shao, J; Song, Y | 1 |
Bestwick, CS; Milne, L | 1 |
Barnett, MJ; Forrest, DL; Hogge, DE; Johny, A; Lavoie, JC; Le, A; Nantel, SH; Nevill, TJ; Nitta, JY; Shepherd, JD; Smith, CA; Song, KW; Sutherland, HJ; Toze, CL | 1 |
Chen, GQ; Gu, ZM; Huang, Y; Li, D; Sims, PJ; Wiedmer, T; Xu, HZ; Zhao, KW; Zhao, Q; Zhou, CX | 1 |
Chen, SM; Dong, JX; Liu, YF; Sun, H; Zhang, QT | 1 |
Akutsu, M; Furukawa, Y; Izumi, T; Kano, Y; Kobayashi, H; Mano, H; Tsunoda, S | 1 |
Aoun, M; Beguin, H; Georgala, A; Husson, M; Meuleman, N; Nolard, N; Vekemans, M | 1 |
Cheng, Y; Liu, N; Qi, J; Tan, Y; Xiong, D; Yang, C; Zhou, Y; Zhu, Z | 1 |
Kantidze, OL; Razin, SV | 1 |
Akutsu, M; Furukawa, Y; Izumi, T; Kano, Y; Kirito, K; Mano, H; Matsuo, Y; Odgerel, T; Sato, Y; Tsunoda, S; Vu, HA | 1 |
Kersey, J; Weigel, B; Yao, Q | 1 |
Chen, H; Han, W; Huang, XJ; Liu, DH; Liu, KY; Xu, LP | 1 |
Barberi, W; Foa, R; Giona, F; Malandruccolo, L; Mandelli, F; Martino, P; Moleti, ML; Palumbo, G; Paoloni, F; Pescarmona, E; Testi, AM | 1 |
Barjesteh van Waalwijk van Doorn-Khosrovani, S; Godschalk, RW; Janssen, J; Maas, LM; Nijhuis, JG; van Schooten, FJ | 1 |
Havredaki, M; Scorilas, A; Thomadaki, H; Tsiapalis, CM | 1 |
Bogni, A; Cheng, C; Dolan, ME; Fan, Y; Hartford, C; Liu, W; Neale, G; Pounds, S; Pui, CH; Raimondi, SC; Relling, MV; Treviño, L; Yang, W | 1 |
Fujioka, K; Funabiki, T; Goto, H; Goto, S; Hanzawa, N; Ikuta, K; Izaki, S; Kai, S; Matsuda, M; Okuda, K; Sasaki, H; Sekiguchi, H; Sumita, H; Takahashi, H; Watanabe, Y; Yokota, S | 1 |
Böttger, S; Jerszyk, E; Low, B; Walker, C | 1 |
Hsu, PC; Hung, HC; Liao, YF; Liu, CC; Liu, GY; Tsay, GJ | 1 |
Dahl, GV; Look, AT; Mauer, AM; Rivera, G | 1 |
Bowman, WP; Dahl, GV; Evans, WE; Kalwinsky, D; Look, AT; Rivera, G | 1 |
Gahrton, G | 1 |
Barlogie, B; Cabanillas, F; Freireich, EJ; Keating, M | 1 |
Brunner, KW; Cavalli, F; Goldhirsch, A; Joss, R; Ryssel, HJ; Sonntag, RW | 1 |
Kennedy, BJ; Raghavan, D; Vogelzang, NJ | 1 |
Płuzańska, A; Robak, T | 1 |
Hattori, K; Ito, K; Kobayashi, S; Nakamura, S; Nakanishi, J; Ohtake, S; Yoshida, T | 1 |
Etcubanas, E; Evans, W; Hayes, FA; Hutson, P; Sinkule, JA | 1 |
Arakawa, S; Esumi, N; Imashuku, S | 1 |
Crom, WR; Dow, L; Evans, WE; Look, AT; Rivera, G; Sinkule, JA | 1 |
Cavalli, F; Sauter, C; Varini, M | 1 |
Allan, WP; Fields, AP; Murray, NR; Ritke, MK; Yalowich, JC | 1 |
Csoka, K; Larsson, R; Liliemark, J; Nygren, P | 1 |
Abe, T; Fujii, H; Kuzuyama, Y; Nakagawa, H; Sakabe, H; Sonoda, Y | 1 |
Aarbakke, J; Endresen, PC; Prytz, PS | 1 |
Ichikawa, Y; Kawada, H; Mukaiyama, T; Ogawa, Y; Watanabe, S | 1 |
Gastineau, DA; Hoagland, HC; Letendre, L; Noel, P; Solberg, LA; Tefferi, A | 1 |
Beere, HM; Chapman, RS; Chresta, CM; Dive, C; Heer, S; Herberg, AA; Hickman, JA; Whetton, AD | 1 |
Dubrez, L; Genne, P; Goldwasser, F; Pommier, Y; Solary, E | 1 |
Bernstein, E; Brodsky, I; Bulova, S; Crilley, P; Marks, DI; Mullaney, R; Resnick, K; Styler, MJ; Topolsky, D | 1 |
Beyer, J; Bokemeyer, C; Kuczyk, MA; Schmoll, HJ; Siegert, W | 1 |
Breeden, ES; Einhorn, LH; Loehrer, PJ; Nichols, CR; Williams, SD | 1 |
Collins, R; Fay, J; Herzig, G; Pineiro, L | 1 |
Amylon, MD; Blume, KG; Chao, NJ; Kusnierz-Glaz, C; Long, GD; Negrin, RS | 1 |
Felix, CA; Hosler, MR; Lange, BJ; Masterson, M; Wilson, AE; Winick, NJ | 1 |
Abe, T; Kawano, Y; Makimoto, A; Nakagawa, R; Okamoto, Y; Saito, S; Sato, J; Shimizu, T; Suzue, T; Takaue, Y | 1 |
Bokemeyer, C; Schmoll, HJ | 1 |
Ballester, OF; Cooper, BW; Creger, RJ; Elfenbein, GJ; Fields, KK; Hiemenz, JH; Janssen, WE; Lazarus, HM; Perkins, JB; Zorsky, PE | 1 |
Hashimoto, S; Hasuike, T; Hirai, M; Hirai, N; Kou, KR; Ohta, K; Ohta, T; Takekawa, K; Tanaka, K; Yamane, T | 1 |
Berdel, WE; Vogler, WR | 1 |
Allan, WP; Dive, C; Heer, S; Lazo, JS; Ritke, MK; Rusnak, JM; Yalowich, JC | 1 |
Biersack, H; Boege, F; Meyer, P | 1 |
Ellis, AL; Nowak, B; Plunkett, W; Zwelling, LA | 1 |
Benson, E; Bishop, J; Bradstock, K; Matthews, J; Page, F | 1 |
Allan, WP; Fattman, C; Gunduz, NN; Ritke, MK; Yalowich, JC | 1 |
Muggia, FM | 1 |
Kobayashi, K; Ratain, MJ | 2 |
Andersson, BS; Dimopoulos, M; Gajewski, J; Giralt, SA; Khouri, I; LeMaistre, CF; Mehra, R; Przepiorka, D; Van Besien, K; Vriesendorp, HM | 1 |
Bowman, WP; Dubowy, R; Land, V; Parmley, RT; Pollock, BH; Pratt, C; Sadowitz, PD; Souid, A; Vats, T; Weinstein, H | 1 |
Bastie, JN; Baumelou, E; Casassus, P; Coloma, F; Delmas-Marsalet, B; Delmer, A; Faussat Suberville, AM; Leroux, G; Marie, JP; Rio, B | 1 |
Fujioka, K; Funabiki, T; Ikuta, K; Kai, S; Kajigaya, Y; Matsuyama, S; Sakai, H; Sekiguchi, H; Sumita, H; Takahashi, H | 1 |
Davidson, A; Lewis, I; Pearson, AD; Pinkerton, CR; Stevens, MC | 1 |
Benz, G; Gmür, J; Gubler, J | 1 |
Evans, WE; McLeod, HL | 1 |
Nomura, T; Ogata, K | 1 |
Gantchev, T; Kagan, V; Stoyanovsky, D; Yalowich, J | 1 |
Cahill, R; Deeg, HJ; Gadner, H; Ortlieb, M; Peters, C; Spitzer, TR; Tefft, MC; Torrisi, J; Urban, C | 1 |
Bokemeyer, C; Poliwoda, H; Schmoll, HJ | 1 |
Aricò, M; Broadbent, V; Gadner, H; Grois, N; Jacobson, A; Komp, D; Ladisch, S; Nicholson, HS | 1 |
Ritke, MK; Yalowich, JC | 1 |
Altschuler, E; Bales, E; Ellis, AL; Hinds, M; Mayes, J; Soares, L; Zipf, TF; Zwelling, LA | 1 |
Tutschka, PJ | 1 |
Fisher, LM; Patel, S | 1 |
Carter, C; Hodges, S; Lee, EJ; Reck, K; Schiffer, CA | 1 |
Appelbaum, FR; Blume, KG; Forman, SJ; Henslee-Downey, JP; Kopecky, KJ; LeMaistre, CF; Stiff, PJ | 1 |
Ikeda, H; Inoue, T; Masaoka, T; Murayama, S; Ohtani, M; Shibata, H; Song, C; Tang, JT; Teshima, T; Yamazaki, H | 1 |
Brauner, R; Devergie, A; Fischer, A; Fontoura, M; Gluckman, E; Griscelli, C; Michon, J; Prevot-Saucet, C; Souberbielle, JC; Zucker, JM | 1 |
Anderson, JR; Armitage, JO; Bierman, P; Bishop, MR; Cowles, MK; Kessinger, A; Martin-Algarra, S; Reed, E; Tarantolo, S; Vose, JM | 1 |
Elonen, E; Jokipii, A; Lautenschlager, I; Lyytikäinen, O; Ruutu, P; Tiittanen, L | 1 |
Asaka, M; Hara, N; Kawamura, K; Kurosawa, M; Okabe, M; Sakurada, K; Suzuki, S | 1 |
Broeker, PL; Pomykala, H; Rowley, JD; Super, HG; Tanabe, S; Thirman, MJ; Yonebayashi, Y; Zeleznik-Le, N | 1 |
Andrews, F; Bolwell, B; Collins, R; Fay, J; LeFever, A; Levitt, D; List, A; Nemunaitis, J; Pallansch, P; Resta, D; Rosenfeld, CS; Schuster, MW; Taylor, R | 1 |
Bertrand, R; Dubrez, L; Eymin, B; Pommier, Y; Solary, E | 1 |
Ager, S; Baglin, TP; Bass, G; Mahendra, P; Marcus, RE; Richards, EM | 1 |
Akutsu, M; Kano, Y; Suzuki, K; Tsunoda, S | 1 |
Chen, X; Huang, G; Wang, W | 1 |
Allan, WP; Fattman, CL; Hasinoff, BB; Yalowich, JC | 1 |
Frankfurt, OS; Robb, JA; Sugarbaker, EV; Villa, L | 1 |
Doi, T; Kobayashi, D; Koike, K; Kougo, Y; Matsunaga, T; Muramatsu, H; Niitsu, Y; Sakamaki, S; Sato, T; Watanabe, N | 1 |
Higa, T; Kasai, M; Kiyama, Y; Kobayashi, N; Masauzi, N; Naohara, T; Ogasawara, M; Ohizumi, H; Saito, M; Suzuki, G | 1 |
Fraser, MJ; Ireland, CM; Papaioannou, A; Pittman, SM; Tynan, SJ | 1 |
Avalos, BR; Bechtel, TP; Belt, PS; Copelan, EA; Elder, PJ; Ezzone, SA; Hehmeyer, DM; Penza, SL; Scholl, MD | 1 |
Chen, CL; Fuscoe, JC; Liu, Q; Mahmoud, HH; Pui, CH; Relling, MV | 1 |
Allouche, M; Dubrez, L; Eymin, B; Solary, E | 1 |
Gantchev, TG; Hunting, DJ | 1 |
Brodsky, AL; Melero, MJ; Minissale, CJ; Sánchez Avalos, JC | 1 |
Asaka, M; Hashino, S; Imamura, M; Kasai, M; Kobayashi, S; Sakurada, K; Tanaka, J | 1 |
Forman, SJ; Margolin, KA; Wright, C | 1 |
Fales, I; Hrubá, A; Kavan, P; Kobylka, P; Matĕjcková, S; Skala, JP; Starý, J; Vodvárková, S | 1 |
Davey, MW; Davey, RA; Harvie, RM | 1 |
Gupta, E; Ibrahim, N; Li, XG; Mendoza, J; Pantazis, P; Patel, M; Rubin, EH; Saleem, A | 1 |
Catchpoole, DR; Sleiman, RJ; Stewart, BW | 1 |
Amarante-Mendes, GP; Bhalla, K; Green, DR; Huang, Y; Liu, L; Naekyung Kim, C; Perkins, CL | 1 |
Carriço, MK; Coelho, AM; Klumb, CE; Maia, RC; Noronha, H; Ruimanek, VM; Vasconcelos, FC | 1 |
Austin, CA; Frank, AJ; Padget, K; Tilby, MJ; Willmore, E | 1 |
Catovsky, D; Killick, S; Matutes, E; Swansbury, J | 1 |
Azuma, T; Deguchi, S; Hara, M; Harada, M; Kojima, K; Nakao, S; Narumi, H; Omoto, E; Shinagawa, K; Sunami, K; Takamatsu, H | 1 |
Davey, MW; Davey, RA; Grech, KV | 1 |
Bajorin, D; Cheung, NK; Heller, G; Kramer, K; Kushner, BH; Meyers, PA; Polyak, T; Wollner, N | 1 |
Abboudi, Z; Abrahamson, G; Apperley, JF; Chilcott, S; Craddock, C; Davis, J; Kanfer, EJ; MacDonald, C; Macdonald, D; McGuigan, D; Newlands, ES; Olavarria, E; Philpott, N; Rustin, GJ; Samson, D; Seckl, MJ; Sekhar, M; Stern, S | 1 |
Chanock, SJ; Hiraoka, W; Nieves-Neira, W; Pommier, Y; Vazquez, N | 1 |
Bruntsch, U; Diehl, V; Dölken, G; Engert, A; Franklin, J; Hasenclever, D; Koch, P; Lathan, B; Loeffler, M; Müller, U; Pfreundschuh, M; Rüffer, U; Schalk, KP; Schmitz, N; Schwieder, G; Sieber, M; Tesch, H; Tirier, C; Worst, P; Wulf, G | 1 |
Auner, H; Emmerich, B; Hass, R; Meinhardt, G; Roth, J; Totok, G | 1 |
Anderson, JR; Arthur, D; Catalano, PJ; Freidlin, B; Heyn, R; Khayat, A; Krailo, M; Land, VJ; Miser, J; Rubinstein, L; Shuster, J; Smith, MA; Vena, D | 1 |
Camera, A; Catalano, L; Picardi, M; Rotoli, B; Selleri, C | 1 |
Alessandrino, EP; Bernasconi, C; Bernasconi, P; Bonfichi, M; Caldera, D; Colombo, A; Malcovati, L; Martinelli, G; Pagnucco, G; Salvaneschi, L | 1 |
Droin, N; Eymin, B; Haugg, M; Munsch, B; Solary, E; Sordet, O; Van de Craen, M; Vandenabeele, P | 1 |
Boos, J; Gumbinger, HG; Hempel, G; Jürgens, H; Wagner, A | 1 |
Andoh, T | 1 |
Albertioni, F; Eriksson, S; Keszler, G; Sasvári-Székely, M; Spasokoukotskaja, T; Staub, M | 1 |
Arber, DA; Bhatia, R; Bhatia, S; Forman, SJ; Fung, H; Kashyap, A; Krishnan, A; Molina, A; Nademanee, A; Niland, JC; O'Donnell, MR; Parker, PA; Slovak, ML; Sniecinski, I; Snyder, DS; Spielberger, R; Stein, A | 1 |
Engel, R; Gump, JL; Sullivan, DM; Valkov, NI | 1 |
Abboud, CN; Constine, LS; DiPersio, JF; Duerst, RE; Horan, JT; Liesveld, JL; Passarell, JA; Raubertas, RF; Senf, ES; Zwetsch, LM | 1 |
Carton, J; Hannun, YA; Meredith, F; Perry, DK; Shah, AK; Uhlinger, DJ | 1 |
Cotter, FE; Fennell, DA | 1 |
Capranico, G; D'Incalci, M; Giaccone, G | 1 |
Johnson, LM; Lorico, A; Murren, JR; Rappa, G; Sartorelli, AC | 1 |
Esche, H; Opalka, B; Parssanedjad, K; Pützer, BM; Stiewe, T | 1 |
Bhalla, K; Nguyen, D; Perkins, C; Ramadevi, N; Wen, J; Worthington, E | 1 |
Laroche-Clary, A; Larrue, A; Robert, J | 1 |
Bajwa, RP; Reid, MM; Skinner, R; Wariyar, UK; Windebank, KP | 1 |
Kancherla, R; Nair, JS; Seiter, K; Traganos, F; Tse-Dinh, YC | 1 |
Kim, S; Kim, SH; Kim, WK; Lee, JH; Lee, JS; Lee, KH; Seol, M | 1 |
Hedley, DW; Pham, NA | 1 |
Bertrand, R; Bichat, F; Droin, N; Hammann, A; Rébé, C; Solary, E | 1 |
Ancín, I; Berlanga, JJ; Ferrá, C; Gallardo, D; González, JR; Grañena, A; Marín, D; Muñoz, J; Peris, J; Sarrá, J | 1 |
Bruey, JM; Corcos, L; Garrido, C; Leroy, I; Lizard, G; Miguet, C; Plenchette, S; Rébé, C; Solary, E; Sordet, O | 1 |
Antin, J; Ault, K; Elias, A; Ibrahim, J; Khurshid, A; Mauch, P; Wheeler, C | 1 |
Bohgaki, T; Kohno, M; Kondo, M; Mukai, M; Notoya, A | 1 |
Jia, L; Kelsey, SM; Liu, KZ; Mantsch, HH; Newland, AC | 1 |
Baker, RK; Irons, RD; Kroll, DJ; Kurz, EU; Pyatt, DW | 1 |
Alnemri, ES; Fernandes-Alnemri, T; Jia, L; Kelsey, SM; Newland, AC; Patwari, Y; Srinivasula, SM | 1 |
Grzanka, A | 1 |
Arcese, W; Cerretti, R; De Felice, L; Donato, V; Fenu, S; Guglielmi, C; Iori, A; Laurenti, L; Mengarelli, A; Micozzi, A; Romano, A; Torromeo, C | 1 |
Albertioni, F; Fredriksson, E; Liliemark, E; Ljungquist, S; Polischouk, A; Soderhall, S | 1 |
Al-Jefri, A; Al-Mahr, M; Ayas, M; Belgaumi, A; Leung, W; Solh, H | 1 |
Fraser, AV; Wallace, HM; Woster, PM | 1 |
Wiernik, PH | 1 |
Bunn, PA; Ihde, DC; Radice, PA | 1 |
Amiel, JL; Berger, R; Rouesse, J | 1 |
Henney, JE; Muggia, FM; Rozencweig, M; Von Hoff, DD | 1 |
Crooke, ST; Issell, BF | 1 |
Crooke, ST; Gutierrez, ML | 1 |
Illiger, HJ; Labedzki, L | 1 |
Dubovsky, D; Jacobs, P; Kernoff, L | 1 |
Biersack, H; Boege, F; Gieseler, F; Meyer, P | 1 |
Lorico, A; Rappa, G; Sartorelli, AC | 1 |
Ashihara, E; Fujita, N; Goto, H; Inaba, T; Ito, K; Murakami, S; Okawa, K; Oku, N; Shimazaki, C; Tsuji, H | 1 |
Dan, K; Gomi, S; Ito, T; Nomura, T; Ogata, K; Ohki, I; Tanabe, Y; Yamada, T | 1 |
Aihara, M; Blume, KG; Chao, NJ; Kühl, JS; Sikic, BI | 1 |
Fay, JW; Harden, EA; Herzig, GP; Herzig, RH; Heye, MM; Meagher, RC; Montes, VM; Stevens, DA | 1 |
Copelan, EA | 1 |
Blume, KG; Forman, SJ | 1 |
Andersson, BS; Brunner, LJ; Huan, SD; LeMaistre, CF; Spencer, V; Spinolo, JA; Spitzer, G; Wallerstein, RO; Woo, SY; Yau, JC | 1 |
Appelbaum, FR; Bensinger, WI; Buckner, CD; Clift, RA; Deeg, HJ; Petersen, FB; Sanders, JE; Storb, R; Sullivan, KM; Witherspoon, RP | 1 |
Busch, FW; Ehninger, G; Hiddemann, W; Jaschonek, K; Proksch, B; Schleyer, E; Schmidt, H; Schuler, U; Wanner, T | 1 |
Nakamura, T; Ueda, T | 1 |
Altschuler, E; Chan, D; Hinds, M; Mayes, J; Zwelling, LA | 1 |
Aihara, M; Aihara, Y; Blume, KG; Chao, NJ; Schmidt-Wolf, G; Schmidt-Wolf, I; Sikic, BI | 1 |
Rybka, WB | 1 |
Hattori, M; Kuga, T; Makishima, M; Sampi, K | 1 |
Bierman, PJ; Dennison, JD; Gordon, BG; Klassen, L; Kumar, PP; McGuire, TR; Reed, EC; Sanger, WG; Vaughan, WP; Warkentin, PI | 1 |
Benítez, J; Calabuig, T; Outeiriño, J; Pérez Sáenz, MA; Prieto, E; Rodríguez, C; Sánchez Fayos, J | 1 |
Emminger, W; Emminger-Schmidmeier, W; Gadner, H; Peters, C | 1 |
Butturini, A; Gale, RP; Reizenstein, P | 1 |
Diedrich, H; Freund, M; LeBlanc, S; Link, H; Poliwoda, H; Wilke, HJ | 1 |
Brashear, T; Fay, J; Miller, G; Stone, M | 1 |
Larsson, R; Nygren, P | 1 |
Anasetti, C; Appelbaum, FR; Beatty, P; Doney, K; Martin, P; Pepe, M; Stewart, P; Storb, R; Sullivan, KM; Witherspoon, R | 1 |
Aihara, M; Blume, KG; Chao, NJ; Sikic, BI | 1 |
Broustet, A; Cony, P; Duclos, F; Marit, G; Puntous, M; Reiffers, J | 1 |
Bolwell, BJ; Brown, RA; Frei-Lahr, D; Hande, KR; Harden, EA; Herzig, GP; Herzig, RH; Lowder, JN; Pineiro, L; Wolff, SN | 1 |
Gulati, SC; Lemoli, RM | 1 |
Danno, K; Hamato, N; Kobashi, Y; Ohno, S; Ohno, Y; Ohta, M; Tomii, K; Yamamoto, M; Yokoo, T | 1 |
Lampkin, BC | 1 |
Colvin, OM; Santos, GW | 1 |
Dahl, GV; Jackson, CW; Kalwinsky, DK; Look, AT; Mirro, J | 1 |
Castleberry, R; Hakami, N; Harris, R; Krischer, J; Look, AT; Ravindranath, Y; Steuber, PC; Vietti, TJ | 1 |
DeVita, VT; Glatstein, E; Ihde, DC; Jaffe, ES; Longo, DL; Young, RC | 1 |
Douay, L | 1 |
Clemens, MR; Ehninger, G; Gey, KF; Ladner, C | 1 |
Anas, N; Cairo, MS; Sender, L; Siegel, S | 1 |
Bauer, H; Fehrentz, D; Hunstein, W; Keilholz, U; Körbling, M | 1 |
Bregni, M; Gianni, AM; Siena, S; Tarella, C | 1 |
Hamada, H; Ishida, Y; Minato, K; Ohtsu, T; Shimoyama, M; Sugimoto, Y; Tobinai, K; Tsuruo, T | 1 |
Furukawa, Y; Im, T; Inoue, T; Kishida, T; Park, K; Sasaki, A; Tatsumi, N; Yamane, T | 1 |
Jones, RJ; Santos, GW | 1 |
Kumano, N; Motomiya, M; Oizumi, K; Saijo, Y; Satoh, K; Tokue, Y | 1 |
Bernasconi, C | 1 |
Cahill, R; Cottler-Fox, M; Deeg, HJ; Greenspan, A; Lynch, M; Spitzer, TR; Torrisi, J | 1 |
Cassileth, PA; Gale, RP; Stadtmauer, EA | 1 |
McVie, G; Muggia, FM | 1 |
Bitran, JD; Hoffman, PC; Kaminer, LS; Larson, RA; Le Beau, MM; Purl, S; Ratain, MJ; Skosey, C; Vardiman, JW; Wade, J | 1 |
Edwards, CM; Glisson, BS; King, CK; Ross, WE; Smallwood-Kentro, S | 1 |
Andersson, BS; Bakic, M; Beran, M; Chan, D; Estey, E; Ricketts, L; Silberman, L; Zwelling, LA | 1 |
Beck, WT; Cirtain, MC; Danks, MK; Schmidt, CA; Suttle, DP | 1 |
Alonso, MT; Leyland-Jones, B; Marsoni, S; O'Dwyer, PJ; Wittes, RE | 1 |
Hansen, HH; Hansen, M; Osterlind, K; Pedersen, AG; Pedersen-Bjergaard, J; Philip, P | 1 |
White, JC; Wright, SE | 1 |
Akaboshi, M; Kanamaru, A; Kobayashi, Y; Kohsaki, M; Miyawaki, S; Mizoguchi, H; Nagai, K; Sawamura, M; Takaku, F; Tsuchiya, J | 1 |
Brix, F; Gassmann, W; Heit, W; Hertenstein, B; Holthuis, JJ; Johannson, W; Rister, M; Schaub, J; Schmitz, N; Suttorp, M | 1 |
Araki, Y; Makino, S; Seita, M; Tamura, K | 1 |
Hervé, P; Tamayo, E | 1 |
Behm, F; Dahl, GV; Kalwinsky, D; Mason, C; Mirro, J; Schell, M | 1 |
Hiddemann, W; Kreutzmann, H; Maschmeyer, G; Wendt, F | 1 |
Gratwohl, A; Häfliger, B; Speck, B; Tichelli, A; Würsch, A | 1 |
Amadori, S; Avvisati, G; Mandelli, F; Meloni, G; Petti, MC; Tafuri, A | 1 |
Ibrahim, NK; Khouri, FP; Salem, PA | 1 |
Hiyoshi, M; Kawarabayashi, K; Kishida, T; Kojima, K; Sagawa, H; Sannomiya, Y; Sasaki, A; Yamane, T; Yokomatsu, Y; Yoshikawa, T | 1 |
Bishop, JF; Cobcroft, R; Dodds, A; Joshua, DE; Kronenberg, H; Lowenthal, RM; Manoharan, A; Whiteside, MG; Wolf, M | 1 |
Dalton, RJ; Gerstner, JB; Letendre, L; Levitt, R; Mailliard, JA; Pierre, RV; Therneau, TM | 1 |
Horiuchi, A; Kanamaru, A; Kawagoe, H; Kitani, T; Kohsaki, M; Masaoka, T; Nagai, K; Shibata, H; Tagawa, S; Tsubaki, K | 1 |
Carella, AM; Cerri, R; Congiu, A; Damasio, E; Gaozza, E; Giordano, D; Martinengo, M; Nati, S; Risso, M; Santini, G | 1 |
Appelbaum, FR; Buckner, CD | 1 |
Lampkin, BC; Wong, KY | 1 |
Creger, RJ; Diaz, D; Lazarus, HM | 1 |
Andreeff, M; Ciobanu, N; Paietta, E; Papenhausen, P; Wiernik, PH | 1 |
Dicke, KA; Horwitz, LJ; Jagannath, S; Keating, M; McCredie, KB; Spitzer, G; Vellekoop, L; Zander, AR | 1 |
Blume, KG; Doroshow, JH; Fahey, JL; Forman, SJ; Krance, RA; Metter, GE; Nademanee, AP; O'Donnell, MR; Schmidt, GM; Snyder, DS | 1 |
Amos, D; Appelbaum, FR; Goldberg, RS; Livingston, RB; Mortimer, J; Tallman, MS; Thomas, ED; Weiden, PL | 1 |
Ando, Y | 1 |
Abrams, RA; Anderson, T; Hansen, RM; Hanson, G | 1 |
Ogawa, M | 1 |
Andersson, BS; Beran, M; McCredie, KB; Odaimi, M | 1 |
Castro-Malaspina, H; Gulati, SC; Kushner, BH; Kwon, JH | 1 |
Anderson, NR; Arkin, CF; Bern, MM; Corkery, JC; Huberman, MS; Lokich, JJ; Paul, SD; Phillips, DF; Sonneborn, HA; Wallach, SR | 1 |
Abe, T; Kariyone, S; Maekawa, I; Maekawa, T; Miura, A; Miura, Y; Moriyama, Y; Shibata, A; Wakui, A; Yoshida, Y | 1 |
Hinemann, V; Hoagland, HC; Kovach, JS; Letendre, L | 1 |
Carella, AM; Cerri, R; Congiu, A; Frassoni, F; Giordano, D; Marmont, A; Martinengo, M; Nati, S; Risso, M; Santini, G | 1 |
Bassez, T; David, JC; Maniey, D; Rusquet, R | 1 |
Jacobs, P | 1 |
Kimura, K; Yamada, K; Yoshida, T | 1 |
Arakawa, S; Esumi, N; Imashuku, S; Todo, S | 1 |
Hines, LH; Rathmell, JP; White, JC | 1 |
34 review(s) available for etoposide and Leukemia
Article | Year |
---|---|
Cutaneous manifestations in leukemia patients.
Topics: Adenine Nucleotides; Antineoplastic Agents; Arabinonucleosides; Clofarabine; Cytarabine; Dermatomycoses; Etoposide; Humans; Leukemia; Mastocytosis; Niacinamide; Paraneoplastic Syndromes; Phenylurea Compounds; Skin Diseases, Bacterial; Skin Neoplasms; Sorafenib | 2016 |
[Significance of intensified conditioning regimen for allogeneic hematopoietic stem cell transplantation for treatment of acute leukemias].
Topics: Acute Disease; Cyclophosphamide; Cytarabine; Etoposide; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Melphalan; Recurrence; Risk; Transplantation Conditioning; Transplantation, Homologous; Whole-Body Irradiation | 2011 |
High-dose etoposide in allogeneic stem cell transplantation.
Topics: Adenine Nucleotides; Anthracyclines; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Busulfan; Carboplatin; Carmustine; Clinical Trials as Topic; Clofarabine; Cyclophosphamide; Dose Fractionation, Radiation; Drug Administration Schedule; Etoposide; Humans; Ifosfamide; Leukemia; Leukemia, Myeloid, Acute; Lomustine; Mucositis; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Radiotherapy, Adjuvant; Severity of Illness Index; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Whole-Body Irradiation | 2012 |
Experience with platinum-based and high-dose chemotherapy in patients with gestational trophoblastic disease: possible implications for future management.
Topics: Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Etoposide; Female; Gestational Trophoblastic Disease; Humans; Leukemia; Pregnancy; Uterine Neoplasms | 2004 |
Toxicity of the topoisomerase II inhibitors.
Topics: Antineoplastic Agents; Cardiovascular Diseases; Daunorubicin; Doxorubicin; Enzyme Inhibitors; Epirubicin; Etoposide; Humans; Idarubicin; Leukemia; Middle Aged; Mitoxantrone; Mucositis; Podophyllotoxin; Teniposide; Topoisomerase II Inhibitors; Vascular Diseases | 2005 |
Treatment of acute leukemia--advances in chemotherapy, immunotherapy, and bone marrow transplantation.
Topics: Aclarubicin; Acute Disease; Adolescent; Adult; Age Factors; Aminoacridines; Amsacrine; Anthraquinones; Antibodies, Monoclonal; Azacitidine; Bone Marrow Transplantation; Child; Child, Preschool; Drug Administration Schedule; Etoposide; Humans; Ifosfamide; Immunotherapy; Infant; Interferons; Leukemia; Leukemia, Lymphoid; Liposomes; Middle Aged; Mitoxantrone; Naphthacenes; Prognosis; Teniposide; Transplantation, Homologous; Transplantation, Isogeneic; Vinblastine; Vindesine | 1983 |
The hematologic malignancies. Leukemia, lymphoma, and myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Interferons; Leukemia; Lymphoma; Mechlorethamine; Multiple Myeloma; Prednisone; Procarbazine; Prognosis; Translocation, Genetic; Vincristine | 1984 |
[Etoposide. A new highly effective cytostatic agent in anaplastic small-cell bronchial carcinoma, other solid tumors and hemoblastoses].
Topics: Bronchial Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Small Cell; Cell Division; Choriocarcinoma; Etoposide; Female; Humans; Leukemia; Liver Neoplasms; Lung Neoplasms; Male; Ovarian Neoplasms; Podophyllotoxin; Pregnancy; Testicular Neoplasms; Uterine Neoplasms | 1981 |
Role of etoposide (VP-16) in preparatory regimens for patients with leukemia or lymphoma undergoing allogeneic bone marrow transplantation.
Topics: Actuarial Analysis; Adolescent; Adult; Bone Marrow Transplantation; Child; Child, Preschool; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Cyclophosphamide; Etoposide; Graft vs Host Disease; Humans; Immunosuppressive Agents; Leukemia; Lymphoma; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Survival Rate; Treatment Outcome; Whole-Body Irradiation | 1994 |
Treatment of testicular cancer and the development of secondary malignancies.
Topics: Antineoplastic Agents; Etoposide; Germinoma; Hodgkin Disease; Humans; Leukemia; Leukemia, Radiation-Induced; Male; Neoplasms, Radiation-Induced; Neoplasms, Second Primary; Testicular Neoplasms | 1995 |
Teniposide: overview of its therapeutic potential in adult cancers.
Topics: Acquired Immunodeficiency Syndrome; Adult; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Etoposide; Female; Genital Neoplasms, Female; Hodgkin Disease; Humans; Leukemia; Lung Neoplasms; Lymphoma; Lymphoma, Non-Hodgkin; Neoplasms; Sarcoma, Kaposi; Teniposide | 1994 |
Pharmacodynamics and long-term toxicity of etoposide.
Topics: Child; Etoposide; Humans; Leukemia; Leukemia, Myeloid, Acute; Male; Neoplasms; Podophyllotoxin; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Testicular Neoplasms | 1994 |
Clinical pharmacokinetics and pharmacodynamics of epipodophyllotoxins.
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Resistance; Etoposide; Humans; Leukemia; Neoplasms; Neoplasms, Second Primary; Teniposide; Topoisomerase II Inhibitors | 1993 |
Application of low-dose etoposide therapy for myelodysplastic syndromes.
Topics: Acute Disease; Adult; Aged; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Leukemia; Male; Middle Aged; Myelodysplastic Syndromes; Survival Rate | 1993 |
[Secondary leukemias after etoposide chemotherapy].
Topics: Carcinoma, Bronchogenic; Dose-Response Relationship, Drug; Etoposide; Humans; Leukemia; Lung Neoplasms; Male; Testicular Neoplasms; Time Factors | 1994 |
Use of busulfan containing chemotherapy for conditioning patients with leukemia for bone marrow allografting.
Topics: Actuarial Analysis; Adult; Bone Marrow Purging; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Cytokines; Etoposide; Graft vs Host Disease; Humans; Leukemia; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Recurrence; Remission Induction; Syndrome; Treatment Outcome; Whole-Body Irradiation | 1993 |
DNA topoisomerase II poisons and inhibitors.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; DNA Topoisomerases, Type II; Drug Resistance, Neoplasm; Enzyme Inhibitors; Etoposide; Humans; Leukemia; Topoisomerase II Inhibitors | 1999 |
VM 26 and VP 16-213: a comparative analysis.
Topics: Animals; Brain Neoplasms; Drug Evaluation; Etoposide; Humans; Kinetics; Leukemia; Lung Neoplasms; Lymphoma; Neoplasms, Experimental; Podophyllotoxin; Teniposide; Urinary Bladder Neoplasms | 1977 |
Etoposide (VP-16-213).
Topics: Adult; Animals; Bone Marrow; Cell Cycle; Child; Digestive System; Drug Therapy, Combination; Etoposide; Female; Humans; Leukemia; Lung Neoplasms; Lymphoma; Male; Mice; Neoplasms; Neoplasms, Experimental; Podophyllotoxin; Rats | 1979 |
Pediatric cancer chemotherapy: an updated review. I. Cis-Diammine--dichloroplatinum II (cisplatin), VM-26 (teniposide), VP-16 (etoposide), mitomycin C.
Topics: Child; Cisplatin; Clinical Trials as Topic; Drug Administration Schedule; Etoposide; Humans; Leukemia; Mitomycins; Neoplasms; Podophyllotoxin; Teniposide | 1979 |
Purging multidrug resistant cells from bone marrow.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Bone Marrow; Bone Marrow Purging; Bone Marrow Transplantation; Complement System Proteins; Drug Resistance; Etoposide; Humans; Leukemia; Mice | 1992 |
Conditioning regimens for allogeneic bone marrow transplantation.
Topics: Anemia, Aplastic; Antilymphocyte Serum; Bone Marrow Purging; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Cytarabine; Etoposide; Humans; Leukemia; Lymphocyte Depletion; Melphalan; T-Lymphocytes; Transplantation, Homologous; Whole-Body Irradiation | 1992 |
High-dose etoposide (VP-16)-containing preparatory regimens in allogeneic and autologous bone marrow transplantation for hematologic malignancies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Chemotherapy, Adjuvant; Etoposide; Humans; Leukemia; Lymphoma; Multiple Myeloma; Whole-Body Irradiation | 1992 |
Autotransplants in leukemia: current state, future progress.
Topics: Bone Marrow Transplantation; Cyclophosphamide; Etoposide; Graft vs Host Disease; Hematopoietic Stem Cells; Humans; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Transplantation, Autologous; Twins, Monozygotic | 1991 |
Aleukemic leukemia cutis.
Topics: Adolescent; Adult; Aged; Biopsy; Etoposide; Female; Humans; Leukemia; Male; Middle Aged; Radiography; Skin Neoplasms | 1990 |
Cell kinetics as related to treatment of patients with acute nonlymphoid leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bone Marrow; Bone Marrow Cells; Cell Cycle; Child; Cytarabine; Daunorubicin; Doxorubicin; Etoposide; Flow Cytometry; Hematopoietic Stem Cells; Humans; Hydrocortisone; Leukemia; Methotrexate; Mitotic Index; Neoplastic Stem Cells; Prednisone; Prognosis; Vincristine | 1985 |
Pharmacological purging of bone marrow with reference to autografting.
Topics: Adolescent; Adult; Animals; Bleomycin; Bone Marrow; Bone Marrow Transplantation; Cell Separation; Child; Child, Preschool; Clinical Trials as Topic; Cyclophosphamide; Drug Evaluation; Etoposide; Graft vs Host Disease; Hematopoietic Stem Cells; Humans; Leukemia; Leukemia, Lymphoid; Lymphoma; Lysophosphatidylcholines; Methylprednisolone; Neoplasms, Experimental; Phospholipid Ethers; Pyrimidinones; Transplantation, Autologous; Transplantation, Isogeneic | 1986 |
Pharmacological bone marrow purging with drugs other than cyclophosphamide derivatives.
Topics: Animals; Antineoplastic Agents; Bleomycin; Bone Marrow; Bone Marrow Transplantation; Etoposide; Humans; Leukemia; Lymphoma; Mice; Mice, Inbred C57BL; Neoplastic Stem Cells; Preoperative Care | 1989 |
[Use of recombinant hematopoietic growth factors after chemotherapy and high-dose chemo-radiotherapy].
Topics: Anemia, Aplastic; Antineoplastic Agents; Colony-Stimulating Factors; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Drug Evaluation; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Melphalan; Neoplasms; Radiotherapy | 1989 |
Etoposide: fifteen years experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Evaluation; Etoposide; Hodgkin Disease; Humans; Leukemia; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Lomustine; Melphalan; Mitoxantrone | 1989 |
Etoposide in leukemia, lymphoma and bone marrow transplantation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Etoposide; Humans; Leukemia; Lymphoma | 1989 |
Etoposide (VP-16-213). Current status of an active anticancer drug.
Topics: Animals; Carcinoma, Small Cell; Clinical Trials as Topic; DNA; Drug Administration Schedule; Drug Evaluation; Drug Evaluation, Preclinical; Drug Resistance; Etoposide; Female; Hodgkin Disease; Humans; Leukemia; Lung Neoplasms; Lymphoma; Male; Mice; Podophyllotoxin; Testicular Neoplasms; Tissue Distribution | 1985 |
Overview of the clinical relevance of autologous bone marrow transplantation.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Drug Evaluation; Drug Resistance; Etoposide; Hodgkin Disease; Humans; Leukemia; Leukemia, Lymphoid; Lymphoma; Melphalan; Neoplasm Recurrence, Local; Neoplasms; Thioguanine; Transplantation, Autologous | 1986 |
Indications for and benefits of intensive therapies in treatment of childhood cancers.
Topics: Acute Disease; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Etoposide; Humans; Leukemia; Leukemia, Lymphoid; Lymphoma; Melphalan; Methotrexate; Neoplasms; Osteosarcoma; Risk; Sarcoma, Ewing | 1986 |
51 trial(s) available for etoposide and Leukemia
Article | Year |
---|---|
Outcome of relapse in children and adolescents with B-cell non-Hodgkin lymphoma and mature acute leukemia: A report from the French LMB study.
Topics: Acute Disease; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Carboplatin; Child; Child, Preschool; Cytarabine; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; France; Humans; Ifosfamide; Infant; Leukemia; Lymphoma, Large B-Cell, Diffuse; Male; Prospective Studies; Recurrence; Rituximab; Survival Rate | 2019 |
Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Cyclophosphamide; Cytarabine; Disease-Free Survival; Etoposide; Female; Humans; Ifosfamide; Immunotherapy; Injections, Spinal; Leukemia; Male; Methotrexate; Middle Aged; Prognosis; Prospective Studies; Remission Induction; Rituximab; Young Adult | 2014 |
Safety, Pharmacokinetics, and Efficacy of Palifermin in Children and Adolescents with Acute Leukemias Undergoing Myeloablative Therapy and Allogeneic Hematopoietic Stem Cell Transplantation: A Pediatric Blood and Marrow Transplant Consortium Trial.
Topics: Acute Disease; Adolescent; Child; Child, Preschool; Cyclophosphamide; Etoposide; Female; Fibroblast Growth Factor 7; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Infant; Leukemia; Male; Myeloablative Agonists; Stomatitis; Transplantation, Homologous; Treatment Outcome; Whole-Body Irradiation | 2016 |
Phase I Trial of Total Marrow and Lymphoid Irradiation Transplantation Conditioning in Patients with Relapsed/Refractory Acute Leukemia.
Topics: Acute Disease; Adolescent; Adult; Bone Marrow; Cyclophosphamide; Dose-Response Relationship, Radiation; Etoposide; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Lymphatic Irradiation; Male; Middle Aged; Recurrence; Salvage Therapy; Survival Analysis; Transplantation Conditioning; Young Adult | 2017 |
A multi-center phase I study of clofarabine, etoposide and cyclophosphamide in combination in pediatric patients with refractory or relapsed acute leukemia.
Topics: Acute Disease; Adenine Nucleotides; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Chemical and Drug Induced Liver Injury; Child; Child, Preschool; Clofarabine; Cyclophosphamide; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Infant; Leukemia; Leukemia, Myeloid, Acute; Maximum Tolerated Dose; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Remission Induction; Salvage Therapy; Treatment Outcome; Young Adult | 2009 |
Phase-2 trial of an intensified conditioning regimen for allogeneic hematopoietic cell transplant for poor-risk leukemia.
Topics: Adult; Busulfan; Combined Modality Therapy; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Male; Middle Aged; Recurrence; Risk Factors; Transplantation Conditioning; Transplantation, Homologous; Whole-Body Irradiation; Young Adult | 2011 |
Treatment of refractory acute leukemia with timed sequential chemotherapy using topotecan followed by etoposide + mitoxantrone (T-EM) and correlation with topoisomerase II levels.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; DNA Fragmentation; DNA Topoisomerases, Type II; Enzyme Induction; Etoposide; Female; Humans; Leukemia; Male; Middle Aged; Mitoxantrone; Topotecan | 2002 |
Peripheral blood stem cell collection in children with acute leukemia: effectiveness of the 'DIAVE' mobilizing regimen.
Topics: Acute Disease; Adolescent; Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Cell Count; Child; Child, Preschool; Cytarabine; Dexamethasone; Etoposide; Graft Survival; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Idarubicin; Leukapheresis; Leukemia; Peripheral Blood Stem Cell Transplantation; Vincristine | 2002 |
A phase I dose-escalation study of etoposide continuous infusion added to busulphan/cyclophosphamide as conditioning prior to autologous or allogeneic stem cell transplantation.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Etoposide; Female; Graft Survival; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Lymphoma; Male; Maximum Tolerated Dose; Middle Aged; Mucous Membrane; Stomatitis; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous | 2002 |
Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; Cyclophosphamide; Dacarbazine; Dose-Response Relationship, Drug; Doxorubicin; Etoposide; Female; Hodgkin Disease; Humans; Leukemia; Male; Middle Aged; Neoplasm Staging; Neoplasms, Second Primary; Prednisone; Procarbazine; Survival Analysis; Vinblastine; Vincristine | 2003 |
Therapy-related myelodysplasia and leukemia occur infrequently following VP-16 priming and autotransplantation without total body irradiation.
Topics: Adolescent; Adult; Aged; Breast Neoplasms; Etoposide; Female; Hematopoietic Stem Cell Mobilization; Humans; Incidence; Leukemia; Lymphoma; Male; Middle Aged; Neoplasms, Second Primary; Neural Tube Defects; Peripheral Blood Stem Cell Transplantation; Probability; Transplantation, Autologous | 2004 |
Glomerular dysfunction, independent of tubular dysfunction, induced by antineoplastic chemotherapy in children.
Topics: Acute Disease; Adolescent; Albuminuria; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Creatinine; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Glomerular Filtration Rate; Humans; Kidney Tubules; Leukemia; Lymphoma; Methotrexate; Neoplasms; Neuroblastoma; Osteosarcoma; Proteinuria; Rhabdomyosarcoma; Vincristine | 2004 |
A phase I and pharmacologic study of idarubicin, cytarabine, etoposide, and the multidrug resistance protein (MDR1/Pgp) inhibitor PSC-833 in patients with refractory leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclosporins; Cytarabine; Drug Interactions; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Idarubicin; Leukemia; Male; Maximum Tolerated Dose; Middle Aged; Treatment Outcome | 2005 |
Donor lymphocyte infusion for the treatment of leukemia relapse after HLA-mismatched/haploidentical T-cell-replete hematopoietic stem cell transplantation.
Topics: Adolescent; Adult; Antineoplastic Agents; Benzamides; Child; Combined Modality Therapy; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Graft vs Host Disease; Graft vs Leukemia Effect; Haplotypes; Histocompatibility; HLA Antigens; Humans; Imatinib Mesylate; Immunosuppressive Agents; Kaplan-Meier Estimate; Leukemia; Lymphocyte Transfusion; Male; Methotrexate; Mitoxantrone; Pancytopenia; Peripheral Blood Stem Cell Transplantation; Piperazines; Pyrimidines; Recurrence; Remission Induction; Salvage Therapy; Tissue Donors; Treatment Outcome | 2007 |
VP-16-213 (etoposide): the mandrake root from Issyk-Kul.
Topics: Animals; Breast Neoplasms; Carcinoma, Small Cell; Cell Cycle; Chemical Phenomena; Chemistry; Clinical Trials as Topic; Dysgerminoma; Etoposide; Female; Humans; Leukemia; Lung Neoplasms; Lymphoma; Mice; Podophyllotoxin | 1982 |
[New antineoplastic drugs of the podophyllotoxin derivative group].
Topics: Adult; Child; Clinical Trials as Topic; Etoposide; Female; Humans; Leukemia; Lung Neoplasms; Lymphoma; Neoplasms; Ovarian Neoplasms; Podophyllotoxin; Teniposide; Urinary Bladder Neoplasms | 1983 |
[Phase II study of etoposide (NK 171) in advanced hematological malignancies].
Topics: Administration, Oral; Adolescent; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Drug Evaluation; Etoposide; Female; Humans; Infusions, Parenteral; Leukemia; Leukopenia; Lymphoma; Male; Middle Aged; Nausea; Podophyllotoxin; Prednisolone; Thrombocytosis; Vincristine | 1984 |
Peripheral blood stem cell mobilization with chemotherapy and granulocyte-colony stimulating factor in patients with hematological malignancies.
Topics: Adolescent; Adult; Antigens, CD34; Colony-Forming Units Assay; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Leukapheresis; Leukemia; Leukocyte Count; Lymphoma; Male; Middle Aged | 1994 |
Continuous infusion etoposide/carboplatin for treatment of refractory acute leukemia.
Topics: Adolescent; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Female; Humans; Infusions, Intravenous; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Salvage Therapy | 1995 |
Bone marrow purging with etoposide/methylprednisolone in patients undergoing autologous bone marrow transplantation.
Topics: Adolescent; Adult; Aged; Bone Marrow Purging; Bone Marrow Transplantation; Child; Etoposide; Humans; Leukemia; Leukocyte Count; Lymphoma; Methylprednisolone; Middle Aged; Neutrophils; Platelet Count; Transplantation, Autologous | 1994 |
Role of etoposide (VP-16) in preparatory regimens for patients with leukemia or lymphoma undergoing allogeneic bone marrow transplantation.
Topics: Actuarial Analysis; Adolescent; Adult; Bone Marrow Transplantation; Child; Child, Preschool; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Cyclophosphamide; Etoposide; Graft vs Host Disease; Humans; Immunosuppressive Agents; Leukemia; Lymphoma; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Survival Rate; Treatment Outcome; Whole-Body Irradiation | 1994 |
Maximum-tolerated doses of ifosfamide, carboplatin, and etoposide given over 6 days followed by autologous stem-cell rescue: toxicity profile.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Drug Tolerance; Etoposide; Female; Germinoma; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Ifosfamide; Leukemia; Lymphoma, Non-Hodgkin; Male; Middle Aged; Ovarian Neoplasms; Prognosis; Sarcoma; Testicular Neoplasms; Transplantation, Autologous | 1995 |
Autologous bone marrow transplantation with alkyl-lysophospholipid-purged marrow.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Bone Marrow Transplantation; Combined Modality Therapy; Cryopreservation; Cyclophosphamide; Cytarabine; Etoposide; Female; Hematopoietic Stem Cells; Humans; Infections; Leukemia; Life Tables; Male; Middle Aged; Neoplastic Stem Cells; Phospholipid Ethers; Salvage Therapy; Survival Analysis; Tissue Preservation; Whole-Body Irradiation | 1993 |
Prognostic value of immunophenotyping in acute myeloid leukemia. Australian Leukaemia Study Group.
Topics: Acute Disease; Adolescent; Adult; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Daunorubicin; Etoposide; Follow-Up Studies; HLA-DR Antigens; Humans; Immunophenotyping; Leukemia; Middle Aged; Predictive Value of Tests; Prognosis; Survival Analysis; Time Factors | 1994 |
Phase I trial of continuous infusion carboplatin and etoposide in children with refractory acute leukemia: a Pediatric Oncology Group study.
Topics: Acute Disease; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carboplatin; Child; Child, Preschool; Diarrhea; Drug Administration Schedule; Etoposide; Female; Humans; Infections; Infusions, Intravenous; Leukemia; Male; Remission Induction; United States | 1994 |
Cyclosporin A as a modifier agent in the salvage treatment of acute leukemia (AL).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carrier Proteins; Cyclosporine; Etoposide; Female; Humans; Leukemia; Male; Membrane Glycoproteins; Middle Aged; Mitoxantrone | 1993 |
[High-dose busulfan, VP-16 and ACNU therapy with stem cell transplantation for the treatment of children with acute leukemia].
Topics: Acute Disease; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Carmustine; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Male; Nimustine | 1993 |
LCH-I: a randomized trial of etoposide vs. vinblastine in disseminated Langerhans cell histiocytosis. The Histiocyte Society.
Topics: Drug Administration Schedule; Etoposide; Histiocytosis, Langerhans-Cell; Humans; Leukemia; Methylprednisolone; Vinblastine | 1994 |
A phase I trial of carboplatin and etoposide given as continuous infusions to adults with leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Carboplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Humans; Infusions, Intravenous; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1993 |
A prospective randomized comparison of total body irradiation-etoposide versus busulfan-cyclophosphamide as preparatory regimens for bone marrow transplantation in patients with leukemia who were not in first remission: a Southwest Oncology Group study.
Topics: Adolescent; Adult; Aged; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Humans; Leukemia; Male; Middle Aged; Prospective Studies; Remission Induction; Risk Factors; Whole-Body Irradiation | 1993 |
Comparison of four cytokine regimens for mobilization of peripheral blood stem cells: IL-3 alone and combined with GM-CSF or G-CSF.
Topics: Adult; Bone Marrow; Breast Neoplasms; Busulfan; Carboplatin; Carmustine; Cyclophosphamide; Drug Administration Schedule; Drug Synergism; Etoposide; Female; Graft Survival; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Interleukin-3; Leukapheresis; Leukemia; Leukocyte Count; Lymphoma; Male; Middle Aged; Neutrophils; Prospective Studies; Thiotepa; Whole-Body Irradiation | 1996 |
[Treatment of refractory hematologic malignancies by combination of cytarabine ocfosfate and etoposide].
Topics: Acute Disease; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleotides; Cytidine Monophosphate; Drug Administration Schedule; Etoposide; Female; Humans; Leukemia; Male; Middle Aged | 1996 |
[Chemotherapy schedules and bacteremia in adult patients with acute leukemia].
Topics: Acute Disease; Adolescent; Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bacteremia; Cytarabine; Daunorubicin; Drug Therapy, Combination; Etoposide; Female; Humans; Leukemia; Male; Mitoxantrone; Neutropenia; Risk Factors | 1996 |
High risk of leukemia after short-term dose-intensive chemotherapy in young patients with solid tumors.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Cyclophosphamide; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Ifosfamide; Leukemia; Male; Myelodysplastic Syndromes; Neoplasms; Neoplasms, Second Primary; Prospective Studies; Risk Factors; Vincristine | 1998 |
High-dose etoposide with granulocyte colony-stimulating factor for mobilization of peripheral blood progenitor cells: efficacy and toxicity at three dose levels.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Choriocarcinoma; Etoposide; Female; Germinoma; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hodgkin Disease; Humans; Leukemia; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Neoplasms | 1998 |
Moderate dose escalation for advanced stage Hodgkin's disease using the bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone scheme and adjuvant radiotherapy: a study of the German Hodgkin's Lymphoma Study Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hodgkin Disease; Humans; Leukemia; Male; Middle Aged; Neoplasms, Second Primary; Prednisone; Procarbazine; Radiotherapy, Adjuvant; Recombinant Proteins; Remission Induction; Survival Rate; Treatment Outcome; Vincristine | 1998 |
Allogeneic bone marrow transplantation for children with acute leukemia: cytoreduction with fractionated total body irradiation, high-dose etoposide and cyclophosphamide.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Grouping and Crossmatching; Bone Marrow Transplantation; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Evaluation; Drug-Related Side Effects and Adverse Reactions; Etoposide; Graft Survival; Graft vs Host Disease; Humans; Infant; Leukemia; Myeloablative Agonists; Nuclear Family; Recurrence; Stomatitis; Survival Rate; Transplantation, Homologous; Whole-Body Irradiation | 2000 |
Mitoxantrone, etoposide, carboplatinum and ara-C combination therapy (MECA) in refractory and relapsed acute leukemia.
Topics: Actuarial Analysis; Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cytarabine; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Male; Middle Aged; Mitoxantrone; Recurrence; Risk Factors; Salvage Therapy; Treatment Outcome | 2000 |
Therapeutic trials with VP-16-213 and VM-26: active agents in small cell lung cancer, non-Hodgkin's lymphomas, and other malignancies.
Topics: Alopecia; Carcinoma, Small Cell; Clinical Trials as Topic; Drug Evaluation; Etoposide; Humans; Leukemia; Leukopenia; Lung Neoplasms; Lymphoma; Podophyllotoxin; Teniposide | 1979 |
Pediatric cancer chemotherapy: an updated review. I. Cis-Diammine--dichloroplatinum II (cisplatin), VM-26 (teniposide), VP-16 (etoposide), mitomycin C.
Topics: Child; Cisplatin; Clinical Trials as Topic; Drug Administration Schedule; Etoposide; Humans; Leukemia; Mitomycins; Neoplasms; Podophyllotoxin; Teniposide | 1979 |
Etoposide, cyclophosphamide and fractionated total body irradiation as a preparative regimen for marrow transplantation in patients with advanced hematological malignancies: a phase I study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Cyclophosphamide; Etoposide; Graft vs Host Disease; Humans; Leukemia; Lymphoma; Middle Aged; Transplantation, Autologous; Transplantation, Homologous; Whole-Body Irradiation | 1992 |
What role for prednisone in prevention of acute graft-versus-host disease in patients undergoing marrow transplants?
Topics: Acute Disease; Anemia, Aplastic; Bone Marrow Transplantation; Chronic Disease; Clinical Trials as Topic; Cyclophosphamide; Cyclosporins; Etoposide; Female; Follow-Up Studies; Graft vs Host Disease; Histocompatibility Testing; Humans; Immunosuppression Therapy; Leukemia; Male; Methotrexate; Myelodysplastic Syndromes; Prednisone; Random Allocation; Risk Factors; Whole-Body Irradiation | 1990 |
Pharmacological purging of bone marrow with reference to autografting.
Topics: Adolescent; Adult; Animals; Bleomycin; Bone Marrow; Bone Marrow Transplantation; Cell Separation; Child; Child, Preschool; Clinical Trials as Topic; Cyclophosphamide; Drug Evaluation; Etoposide; Graft vs Host Disease; Hematopoietic Stem Cells; Humans; Leukemia; Leukemia, Lymphoid; Lymphoma; Lysophosphatidylcholines; Methylprednisolone; Neoplasms, Experimental; Phospholipid Ethers; Pyrimidinones; Transplantation, Autologous; Transplantation, Isogeneic | 1986 |
Induction failures in childhood acute nonlymphocytic leukemia: etoposide/5-azacytidine for cases refractory to daunorubicin/cytarabine.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Child; Clinical Trials as Topic; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Leukemia; Male | 1986 |
The treatment of indolent lymphomas: watchful waiting v aggressive combined modality treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Evaluation Studies as Topic; Humans; Leucovorin; Leukemia; Leukemia, Radiation-Induced; Lymph Nodes; Lymphoma, Non-Hodgkin; Mechlorethamine; Methotrexate; Neoplasms, Multiple Primary; Neoplasms, Radiation-Induced; Palliative Care; Prednisone; Procarbazine; Random Allocation; Vincristine | 1988 |
Clinical trial of continuous infusion verapamil, bolus vinblastine, and continuous infusion VP-16 in drug-resistant pediatric tumors.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Child; Child, Preschool; Clinical Trials as Topic; Etoposide; Humans; Infusions, Intravenous; Leukemia; Liver Neoplasms; Neuroblastoma; Verapamil; Vinblastine | 1989 |
Etoposide (VP-16-213). Current status of an active anticancer drug.
Topics: Animals; Carcinoma, Small Cell; Clinical Trials as Topic; DNA; Drug Administration Schedule; Drug Evaluation; Drug Evaluation, Preclinical; Drug Resistance; Etoposide; Female; Hodgkin Disease; Humans; Leukemia; Lung Neoplasms; Lymphoma; Male; Mice; Podophyllotoxin; Testicular Neoplasms; Tissue Distribution | 1985 |
[A study of B-triple V (behenoyl-ara C, etoposide, vincristine, vinblastine) in acute leukemia].
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cytarabine; Etoposide; Female; Humans; Leukemia; Male; Middle Aged; Vinblastine; Vincristine | 1988 |
Early intensification of chemotherapy for childhood acute nonlymphoblastic leukemia: improved remission induction with a five-drug regimen including etoposide.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Clinical Trials as Topic; Etoposide; Female; Humans; Infant; Infant, Newborn; Leukemia; Male; Prognosis; Remission Induction | 1988 |
Overview of the clinical relevance of autologous bone marrow transplantation.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Drug Evaluation; Drug Resistance; Etoposide; Hodgkin Disease; Humans; Leukemia; Leukemia, Lymphoid; Lymphoma; Melphalan; Neoplasm Recurrence, Local; Neoplasms; Thioguanine; Transplantation, Autologous | 1986 |
The epipodophyllotoxin VP16-213 in combination chemotherapy for adults with acute nonlymphoblastic leukaemia.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cytarabine; Doxorubicin; Etoposide; Humans; Leukemia; Podophyllotoxin; Thioguanine | 1985 |
266 other study(ies) available for etoposide and Leukemia
Article | Year |
---|---|
Synthesis and pharmacological evaluation of isoindolo[1,2-b]quinazolinone and isoindolo[2,1-a]benzimidazole derivatives related to the antitumor agent batracylin.
Topics: Animals; Antineoplastic Agents; DNA; Humans; Indoles; Isoindoles; Leukemia; Liver; Pyridones; Pyrimidines; Quinazolines; Rats; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 1994 |
Cytotoxic oxoisoaporphine alkaloids from Menispermum dauricum.
Topics: Adenocarcinoma; Alkaloids; Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cytochrome P-450 Enzyme Inhibitors; Drugs, Chinese Herbal; Enzyme Inhibitors; Female; Humans; Leukemia; Lung Neoplasms; Magnetic Resonance Spectroscopy; Mass Spectrometry; Mice; Molecular Structure; Plant Roots; Plants, Medicinal; Porphyrins; Tumor Cells, Cultured | 2001 |
Differential Targeting of Human Topoisomerase II Isoforms with Small Molecules.
Topics: Animals; Antigens, Neoplasm; Cells, Cultured; DNA Topoisomerases, Type II; DNA-Binding Proteins; Etoposide; Humans; Leukemia; Mice; Mice, Knockout; Models, Molecular; Molecular Structure; Poly-ADP-Ribose Binding Proteins; Small Molecule Libraries; Structure-Activity Relationship; Topoisomerase II Inhibitors | 2015 |
Discovery of antitumor anthra[2,3-b]furan-3-carboxamides: Optimization of synthesis and evaluation of antitumor properties.
Topics: Animals; Anthracenes; Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Furans; Humans; Leukemia; Mice; Neoplasms; Protein Kinase Inhibitors; Structure-Activity Relationship; Topoisomerase Inhibitors | 2016 |
Design, synthesis and evaluation of the multidrug resistance-reversing activity of pyridine acid esters of podophyllotoxin in human leukemia cells.
Topics: Cell Line, Tumor; Drug Design; Drug Resistance, Multiple; Esters; Humans; Inhibitory Concentration 50; Leukemia; MAP Kinase Signaling System; Podophyllotoxin; Pyridines | 2016 |
KMT2A-MAML2 rearrangement emerged and regressed during neuroblastoma therapy without leukemia after 12.8-year follow-up.
Topics: Etoposide; Follow-Up Studies; Gene Rearrangement; Histone-Lysine N-Methyltransferase; Humans; Leukemia; Myeloid-Lymphoid Leukemia Protein; Neuroblastoma; Trans-Activators; Transcription Factors | 2022 |
The effect of apigenin and chemotherapy combination treatments on apoptosis-related genes and proteins in acute leukaemia cell lines.
Topics: Apigenin; Apoptosis; Apoptosis Regulatory Proteins; Cell Line; Cyclophosphamide; Drug Therapy, Combination; Etoposide; Humans; Leukemia; Mitochondrial Proteins | 2022 |
Use of CRISPR/Cas9 with homology-directed repair to silence the human topoisomerase IIα intron-19 5' splice site: Generation of etoposide resistance in human leukemia K562 cells.
Topics: Antigens, Neoplasm; CRISPR-Cas Systems; DNA Topoisomerases, Type II; Etoposide; Humans; Introns; K562 Cells; Leukemia; RNA Splice Sites; RNA, Messenger | 2022 |
Inhibition of NAMPT sensitizes MOLT4 leukemia cells for etoposide treatment through the SIRT2-p53 pathway.
Topics: Cell Death; Cell Line, Tumor; Cytokines; Enzyme Inhibitors; Etoposide; Humans; Leukemia; Nicotinamide Phosphoribosyltransferase; Signal Transduction; Sirtuin 2; Topoisomerase II Inhibitors; Tumor Suppressor Protein p53 | 2018 |
Activation of Rac1 GTPase promotes leukemia cell chemotherapy resistance, quiescence and niche interaction.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Movement; Cells, Cultured; Drug Resistance, Neoplasm; Etoposide; Humans; Immunohistochemistry; Leukemia; Mice; Mice, SCID; rac1 GTP-Binding Protein; Reverse Transcriptase Polymerase Chain Reaction; Xenograft Model Antitumor Assays | 2013 |
Wogonin attenuates etoposide-induced oxidative DNA damage and apoptosis via suppression of oxidative DNA stress and modulation of OGG1 expression.
Topics: Animals; Anticarcinogenic Agents; Antioxidants; Apoptosis; Bone Marrow Cells; DNA Damage; DNA Glycosylases; Dose-Response Relationship, Drug; Etoposide; Flavanones; Gene Expression Regulation; Leukemia; Male; Mice; Micronucleus Tests; Mutagenicity Tests; Oxidative Stress; Random Allocation; RNA, Messenger; Topoisomerase II Inhibitors | 2013 |
Down-regulation of Mcl-1 by small interference RNA induces apoptosis and sensitizes HL-60 leukemia cells to etoposide.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Cell Proliferation; Etoposide; Flow Cytometry; Gene Expression Regulation, Neoplastic; Humans; Leukemia; Myeloid Cell Leukemia Sequence 1 Protein; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Tumor Cells, Cultured | 2014 |
Etoposide quinone is a covalent poison of human topoisomerase IIβ.
Topics: DNA; DNA Topoisomerases, Type II; DNA-Binding Proteins; Etoposide; Humans; Leukemia; Neoplasm Proteins; Quinones; Topoisomerase II Inhibitors | 2014 |
Inhibition of miR-17 and miR-20a by oridonin triggers apoptosis and reverses chemoresistance by derepressing BIM-S.
Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Cell Growth Processes; Cytarabine; Diterpenes, Kaurane; Down-Regulation; Etoposide; HL-60 Cells; Humans; K562 Cells; Leukemia; Membrane Proteins; Mice; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Microscopy, Confocal; Proto-Oncogene Proteins; Transfection; Up-Regulation | 2014 |
Schedule-dependent cytotoxicity of Etoposide and cyclophosphamide in P-glycoprotein-expressing human leukemic K-562 cells.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Cell Cycle; Cell Survival; Cyclophosphamide; Drug Administration Schedule; Etoposide; Humans; K562 Cells; Leukemia | 2014 |
Structure-based design, synthesis and biological testing of etoposide analog epipodophyllotoxin-N-mustard hybrid compounds designed to covalently bind to topoisomerase II and DNA.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; DNA; DNA Breaks, Double-Stranded; DNA Topoisomerases, Type II; Etoposide; Humans; Leukemia; Molecular Docking Simulation; Mustard Compounds; Neoplasms; Podophyllotoxin; Topoisomerase II Inhibitors | 2014 |
Environmental and chemotherapeutic agents induce breakage at genes involved in leukemia-causing gene rearrangements in human hematopoietic stem/progenitor cells.
Topics: Benzene; Bone Marrow Cells; Chromosome Breakage; Core Binding Factor beta Subunit; Diethylnitrosamine; DNA Damage; DNA Topoisomerases, Type II; Doxorubicin; Etoposide; Gene Rearrangement; Genome, Human; Hematopoietic Stem Cells; Histone-Lysine N-Methyltransferase; Humans; Leukemia; Myeloid-Lymphoid Leukemia Protein; Primary Cell Culture | 2015 |
Dysregulation of the DNA Damage Response and KMT2A Rearrangement in Fetal Liver Hematopoietic Cells.
Topics: Animals; Bone Marrow Cells; Carcinogenesis; Cell Cycle; Chromosome Breakage; DNA Breaks, Double-Stranded; DNA Damage; Etoposide; Female; Fetus; Gene Rearrangement; Hematopoietic Stem Cells; Histone-Lysine N-Methyltransferase; Histones; Injections, Intraperitoneal; Leukemia; Liver; Maternal Exposure; Mice, Inbred C57BL; Mice, Knockout; Myeloid-Lymphoid Leukemia Protein | 2015 |
MYC/BCL2 double-hit lymphoma/leukemia mimicking acute leukemia at initial presentation.
Topics: Abnormal Karyotype; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Autografts; Cyclophosphamide; Dexamethasone; Diagnosis, Differential; Doxorubicin; Etoposide; Fatal Outcome; Flow Cytometry; Genes, myc; Hematopoietic Stem Cell Transplantation; Humans; Immunophenotyping; In Situ Hybridization, Fluorescence; Leukemia; Leukocytosis; Lymphoma, B-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Multiple Primary; Prednisone; Proto-Oncogene Proteins c-bcl-2; Rituximab; Vincristine | 2016 |
Quercetin alters the DNA damage response in human hematopoietic stem and progenitor cells via TopoII- and PI3K-dependent mechanisms synergizing in leukemogenic rearrangements.
Topics: Adult; Ascorbic Acid; Cell Culture Techniques; Cell Transformation, Neoplastic; Cells, Cultured; Colony-Forming Units Assay; DNA Damage; DNA Repair; DNA Topoisomerases, Type II; Dose-Response Relationship, Drug; Etoposide; Female; Genistein; Hematopoietic Stem Cells; Histone-Lysine N-Methyltransferase; Histones; Humans; Infant; Leukemia; Maternal-Fetal Exchange; Myeloid-Lymphoid Leukemia Protein; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Pregnancy; Quercetin; Signal Transduction; Topoisomerase II Inhibitors | 2017 |
Factors and Costs Associated With Delay in Treatment Initiation and Prolonged Length of Stay With Inpatient EPOCH Chemotherapy in Patients With Hematologic Malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Female; Health Care Costs; Humans; Inpatients; Length of Stay; Leukemia; Lymphoma; Male; Middle Aged; Prednisone; Treatment Outcome; Vincristine | 2017 |
Reduced risk of secondary leukemia with fewer cycles of dose-intensive induction chemotherapy in patients with neuroblastoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cisplatin; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Leukemia; Male; Myelodysplastic Syndromes; Neuroblastoma; Prospective Studies; Remission Induction; Risk Reduction Behavior; Topoisomerase II Inhibitors; Vincristine; Young Adult | 2009 |
Low toxicity of a conditioning with 8-Gy total body irradiation, fludarabine and cyclophosphamide as preparative regimen for allogeneic hematopoietic stem cell transplantation in pediatric hematological malignancies.
Topics: Adolescent; Child; Child, Preschool; Cyclophosphamide; Disease-Free Survival; Etoposide; Female; Graft Survival; Hematopoietic Stem Cell Transplantation; HLA Antigens; Humans; Infant; Leukemia; Male; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2009 |
Molecular targeting of MLL-rearranged leukemia cell lines with the synthetic peptide PFWT synergistically enhances the cytotoxic effect of established chemotherapeutic agents.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Cell Cycle; Cell Proliferation; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 4; Chromosomes, Human, Pair 9; Colony-Forming Units Assay; Cytarabine; DNA-Binding Proteins; Drug Synergism; Etoposide; Gene Rearrangement; Histone-Lysine N-Methyltransferase; Humans; Leukemia; Myeloid-Lymphoid Leukemia Protein; Necrosis; Nuclear Proteins; Peptide Fragments; Transcriptional Elongation Factors; Translocation, Genetic; Tumor Cells, Cultured | 2009 |
PU.1, a novel caspase-3 substrate, partially contributes to chemotherapeutic agents-induced apoptosis in leukemic cells.
Topics: Antineoplastic Agents; Apoptosis; Aspartic Acid; Camptothecin; Caspase 3; Caspase Inhibitors; Cell Line, Tumor; Cysteine Proteinase Inhibitors; Etoposide; Humans; Leukemia; Mutagenesis, Site-Directed; Oligopeptides; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; RNA, Small Interfering; Trans-Activators | 2009 |
siRNA-mediated down-regulation of iASPP promotes apoptosis induced by etoposide and daunorubicin in leukemia cells expressing wild-type p53.
Topics: Antineoplastic Agents; Apoptosis; Base Sequence; Cell Division; Cell Line, Tumor; Daunorubicin; DNA Primers; Down-Regulation; Etoposide; Humans; Intracellular Signaling Peptides and Proteins; Leukemia; Repressor Proteins; RNA, Messenger; RNA, Small Interfering; Tumor Suppressor Protein p53 | 2009 |
Nuclear translocation of dihydrofolate reductase is not a pre-requisite for DNA damage induced apoptosis.
Topics: Amino Acid Sequence; Apoptosis; Camptothecin; Caspase 3; Cell Line, Tumor; Cell Nucleus; DNA Damage; Dose-Response Relationship, Drug; Endoplasmic Reticulum; Enzyme Activation; Etoposide; Humans; Leukemia; Methotrexate; Microtubules; Molecular Sequence Data; Neoplasm Proteins; Protein Transport; Tetrahydrofolate Dehydrogenase | 2009 |
Reversal effect of PI3-K inhibitor LY294002 on P-glycoprotein-mediated multidrug resistance of human leukemia cell line K562/DNR and gastric cancer cell line SGC7901/ADR.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chromones; Daunorubicin; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Enzyme Inhibitors; Etoposide; Humans; K562 Cells; Leukemia; Morpholines; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Stomach Neoplasms; Vincristine | 2009 |
Protein kinase Cdelta stimulates proteasome-dependent degradation of C/EBPalpha during apoptosis induction of leukemic cells.
Topics: Apoptosis; Base Sequence; Blotting, Western; Caspase 3; CCAAT-Enhancer-Binding Protein-alpha; Cell Line, Tumor; DNA Primers; Down-Regulation; Etoposide; Gene Silencing; Humans; Hydrolysis; Leukemia; Proteasome Endopeptidase Complex; Protein Kinase C-delta; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Transcription, Genetic; Ubiquitination | 2009 |
BCR/ABL downregulates DNA-PK(CS)-dependent and upregulates backup non-homologous end joining in leukemic cells.
Topics: Androstadienes; Cell Line, Tumor; Cell Survival; Comet Assay; DNA Breaks, Double-Stranded; DNA Repair; DNA-Activated Protein Kinase; Down-Regulation; Etoposide; Fusion Proteins, bcr-abl; Humans; Leukemia; Nuclear Proteins; Piperazines; Recombination, Genetic; Time Factors; Up-Regulation; Wortmannin | 2010 |
A comparative study of outcomes of idarubicin- and etoposide-intensified conditioning regimens for allogeneic peripheral blood stem cell transplantation in patients with high-risk acute leukemia.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Aspergillus; Busulfan; China; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease-Free Survival; Etoposide; Female; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Hydroxyurea; Idarubicin; Immunosuppressive Agents; Leukemia; Leukemia, Myeloid, Acute; Male; Methylprednisolone; Mucositis; Pneumonia; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Premedication; Retrospective Studies; Risk Factors; Semustine; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Whole-Body Irradiation | 2009 |
The cytotoxic effects of gemtuzumab ozogamicin (mylotarg) in combination with conventional antileukemic agents by isobologram analysis in vitro.
Topics: Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Etoposide; Gemtuzumab; HL-60 Cells; Humans; Idarubicin; Immunotoxins; Leukemia; Mercaptopurine; Methotrexate; Mitoxantrone; Sialic Acid Binding Ig-like Lectin 3; U937 Cells; Vincristine | 2009 |
Etoposide induces more severe mucositis than CY when added to TBI as conditioning in allograft recipients receiving CsA and MTX.
Topics: Adolescent; Adult; Antineoplastic Agents, Phytogenic; Cyclophosphamide; Cyclosporine; Drug Therapy, Combination; Etoposide; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia; Male; Methotrexate; Middle Aged; Mucositis; Retrospective Studies; Severity of Illness Index; Transplantation Conditioning; Transplantation, Homologous; Whole-Body Irradiation; Young Adult | 2010 |
Novel second mitochondria-derived activator of caspases (Smac) mimetic compounds sensitize human leukemic cell lines to conventional chemotherapeutic drug-induced and death receptor-mediated apoptosis.
Topics: Antigens, CD34; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Cell Line, Tumor; Cytarabine; Drug Synergism; Etoposide; Humans; Inhibitor of Apoptosis Proteins; Intracellular Signaling Peptides and Proteins; Leukemia; Mitochondrial Proteins; Protein Binding; Stem Cells; TNF-Related Apoptosis-Inducing Ligand; X-Linked Inhibitor of Apoptosis Protein | 2011 |
Adhesion-induced drug resistance in leukemia stem cells.
Topics: Antineoplastic Agents; Bone Marrow Cells; Cell Adhesion; Cell Cycle; Cell Line, Tumor; Coculture Techniques; Cyclin-Dependent Kinase Inhibitor Proteins; Cytarabine; Daunorubicin; Drug Resistance, Neoplasm; Etoposide; Humans; Leukemia; Lysosomes; Neoplastic Stem Cells; Osmolar Concentration; Proto-Oncogene Proteins c-bcl-2; Stem Cell Niche; Stromal Cells; Up-Regulation; Vacuolar Proton-Translocating ATPases | 2010 |
Vandetanib mediates anti-leukemia activity by multiple mechanisms and interacts synergistically with DNA damaging agents.
Topics: Acute Disease; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Cell Cycle; Cell Proliferation; Cell Survival; DNA Damage; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Etoposide; HL-60 Cells; Humans; Inhibitory Concentration 50; Leukemia; Methotrexate; Piperidines; Protein Kinase Inhibitors; Quinazolines; Topoisomerase II Inhibitors | 2012 |
Cell cycle-dependent priming action of granulocyte colony-stimulating factor (G-CSF) enhances in vitro apoptosis induction by cytarabine and etoposide in leukemia cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cytarabine; Etoposide; Flow Cytometry; Granulocyte Colony-Stimulating Factor; Humans; In Vitro Techniques; Leukemia | 2010 |
Etoposide plus G-CSF priming compared with G-CSF alone in patients with lymphoma improves mobilization without an increased risk of secondary myelodysplasia and leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Etoposide; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Lymphoma; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Risk Factors; Young Adult | 2012 |
In vitro synergism between LFA-1 targeting leukotoxin (Leukothera™) and standard chemotherapeutic agents in leukemia cells.
Topics: Adenosine Triphosphate; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Busulfan; Cell Line, Tumor; Daunorubicin; Drug Interactions; Drug Synergism; Etoposide; Exotoxins; Flow Cytometry; Humans; Imatinib Mesylate; Immunosuppressive Agents; Leukemia; Leukocytes; Lymphocyte Function-Associated Antigen-1; Membrane Potential, Mitochondrial; Mitoxantrone; Piperazines; Pyrimidines; Tumor Cells, Cultured | 2011 |
Sex differences in the GSK3β-mediated survival of adherent leukemic progenitors.
Topics: Adult; Aged; Aged, 80 and over; Antigens, CD34; Antineoplastic Agents, Phytogenic; Blotting, Western; Cell Adhesion; Cell Survival; Cells, Cultured; Etoposide; Female; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; GTP-Binding Proteins; Hematopoietic Stem Cells; Humans; Indoles; Interleukin-3 Receptor alpha Subunit; Leukemia; Male; Maleimides; Middle Aged; Neoplasm Proteins; Neoplastic Stem Cells; Protein Phosphatase 2; Receptors for Activated C Kinase; Receptors, Cell Surface; RNA Interference; Sex Factors; Tumor Cells, Cultured; Young Adult | 2012 |
Cdx2 homeoprotein inhibits non-homologous end joining in colon cancer but not in leukemia cells.
Topics: Antigens, Nuclear; CDX2 Transcription Factor; Cell Line, Tumor; Cell Survival; Colonic Neoplasms; DNA End-Joining Repair; DNA-Activated Protein Kinase; DNA-Binding Proteins; Etoposide; Homeodomain Proteins; Humans; Ku Autoantigen; Leukemia; Protein Interaction Domains and Motifs; Transcription, Genetic; Tumor Suppressor Proteins | 2012 |
Anaphylactic reaction to etoposide phosphate.
Topics: Anaphylaxis; Antineoplastic Agents; Etoposide; Female; Humans; Infant; Leukemia; Organophosphorus Compounds; Skin Neoplasms | 2012 |
Bcl-2, Bcl-x(L), and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells.
Topics: Aniline Compounds; Animals; Apoptosis Regulatory Proteins; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; Bcl-2-Like Protein 11; bcl-X Protein; Biphenyl Compounds; Cell Death; Cytoprotection; Drug Resistance, Neoplasm; Etoposide; Gene Expression Regulation, Neoplastic; Humans; Leukemia; Lymphoma; Membrane Proteins; Mice; Molecular Targeted Therapy; Mutant Proteins; Myeloid Cell Leukemia Sequence 1 Protein; Nitrophenols; Piperazines; Protein Binding; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Sulfonamides | 2012 |
Nature and dynamics of nucleosome release from neoplastic and non-neoplastic cells.
Topics: Apoptosis; Blast Crisis; Cytarabine; Etoposide; Hep G2 Cells; Humans; L-Lactate Dehydrogenase; Leukemia; Neoplasms; Neutrophils; Nucleosomes; Tetradecanoylphorbol Acetate; TNF-Related Apoptosis-Inducing Ligand | 2012 |
Effect of histone deacetylase inhibitors trichostatin A and valproic acid on etoposide-induced apoptosis in leukemia cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Caspase 3; Caspase 7; Drug Synergism; Etoposide; Histone Deacetylase Inhibitors; HL-60 Cells; Humans; Hydroxamic Acids; Leukemia; Membrane Potential, Mitochondrial; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; U937 Cells; Valproic Acid | 2012 |
Schedule-dependent cytotoxicity of etoposide (VP-16) and cyclophosphamide in leukemia cell line K-562.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Cell Cycle; Cell Survival; Cyclophosphamide; Drug Administration Schedule; Etoposide; Humans; K562 Cells; Leukemia | 2012 |
Do transcription factories and TOP2B provide a recipe for chromosome translocations in therapy-related leukemia?
Topics: Anthracyclines; DNA Breaks, Double-Stranded; DNA Topoisomerases, Type II; DNA-Binding Proteins; Epirubicin; Etoposide; Humans; Leukemia; Mitoxantrone; Models, Genetic; Neoplasms, Second Primary; Poly-ADP-Ribose Binding Proteins; Translocation, Genetic | 2012 |
Ataxia telangiectasia mutated-dependent regulation of topoisomerase II alpha expression and sensitivity to topoisomerase II inhibitor.
Topics: Alanine; Antigens, Neoplasm; Ataxia Telangiectasia Mutated Proteins; Cell Cycle Proteins; Cell Line, Tumor; Cell Survival; DNA Damage; DNA Topoisomerases, Type II; DNA-Binding Proteins; Etoposide; Histone-Lysine N-Methyltransferase; Humans; Leukemia; Mutagenesis, Site-Directed; Myeloid-Lymphoid Leukemia Protein; Phosphorylation; Poly-ADP-Ribose Binding Proteins; Protein Serine-Threonine Kinases; Serine; Topoisomerase II Inhibitors; Tumor Suppressor Proteins | 2013 |
Exposure to low concentrations of etoposide reduces the apoptotic capability of leukaemic cell lines.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; bcl-2-Associated X Protein; Cell Division; Chromosome Aberrations; Cisplatin; DNA Damage; DNA, Neoplasm; Drug Resistance, Neoplasm; Enzyme Inhibitors; Etoposide; Flow Cytometry; Humans; Karyotyping; Leukemia; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 2002 |
Limited and optimal sampling strategies for etoposide and etoposide catechol in children with leukemia.
Topics: Analysis of Variance; Area Under Curve; Bayes Theorem; Catechols; Child; Etoposide; Humans; Leukemia; Linear Models; Metabolic Clearance Rate; Models, Biological; Monte Carlo Method; Statistics, Nonparametric | 2002 |
The histone deacetylase inhibitor sodium butyrate induces DNA topoisomerase II alpha expression and confers hypersensitivity to etoposide in human leukemic cell lines.
Topics: Antigens, Neoplasm; Butyrates; DNA Topoisomerases, Type II; DNA-Binding Proteins; DNA, Neoplasm; Dose-Response Relationship, Drug; Enzyme Inhibitors; Etoposide; Histone Deacetylase Inhibitors; Humans; Leukemia; Tumor Cells, Cultured | 2001 |
Commentary: topoisomerases as targets in acute leukemia: I, II, I plus II or none?
Topics: Acute Disease; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; DNA Topoisomerases, Type I; DNA, Neoplasm; Drug Resistance, Neoplasm; Enzyme Inhibitors; Etoposide; Humans; Leukemia; Neoplasm Proteins; Remission Induction; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan; Treatment Outcome | 2003 |
The influence of etoposide on the distribution of tubulin in human leukemia cell line HL-60.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Cell Division; Dose-Response Relationship, Drug; Etoposide; Fluorescent Antibody Technique, Indirect; HL-60 Cells; Humans; Leukemia; Tubulin; Tumor Cells, Cultured | 2003 |
Risk of secondary leukemia after a solid tumor in childhood according to the dose of epipodophyllotoxins and anthracyclines: a case-control study by the Société Française d'Oncologie Pédiatrique.
Topics: Adolescent; Adult; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Bone Marrow; Case-Control Studies; Chemotherapy, Adjuvant; Child; Child, Preschool; Drug Administration Schedule; Etoposide; Female; France; Humans; Leukemia; Male; Multivariate Analysis; Neoplasms; Neoplasms, Second Primary; Radiotherapy, Adjuvant; Risk Assessment; Risk Factors | 2003 |
Endoplasmic reticulum chaperone protein GRP78 protects cells from apoptosis induced by topoisomerase inhibitors: role of ATP binding site in suppression of caspase-7 activation.
Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Binding Sites; Camptothecin; Carrier Proteins; Caspase 7; Caspases; Cell Membrane; Cricetinae; Doxorubicin; Endoplasmic Reticulum; Endoplasmic Reticulum Chaperone BiP; Enzyme Precursors; Etoposide; G1 Phase; Gene Expression; Heat-Shock Proteins; Humans; Leukemia; Molecular Chaperones; Protein Structure, Tertiary; Subcellular Fractions; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Transfection; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 2003 |
DR1-like element in human topoisomerase IIalpha gene involved in enhancement of etoposide-induced apoptosis by PPARgamma ligand.
Topics: Antigens, Neoplasm; Apoptosis; Chromans; DNA Topoisomerases, Type II; DNA-Binding Proteins; Electrophoretic Mobility Shift Assay; Etoposide; Flow Cytometry; Gene Expression; Humans; Jurkat Cells; Leukemia; Ligands; Mutagenesis; Phosphoproteins; Promoter Regions, Genetic; Prostaglandin D2; Receptors, Cytoplasmic and Nuclear; Receptors, Retinoic Acid; Retinoid X Receptors; Thiazoles; Thiazolidinediones; Topoisomerase II Inhibitors; Transcription Factors; Transfection; Troglitazone; Tumor Cells, Cultured | 2003 |
The schedule-dependent effects of etoposide in leukaemic cell lines: a function of concentration and duration.
Topics: Antineoplastic Agents, Phytogenic; Cell Cycle; Cell Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Humans; Leukemia; Time Factors; Tumor Cells, Cultured | 2003 |
Induction of complete remission of hypoplastic leukemia with antithymocyte globulin.
Topics: Adolescent; Anemia, Aplastic; Antilymphocyte Serum; Apoptosis; Bone Marrow Examination; Cyclosporine; Diagnosis, Differential; Etoposide; Humans; Leukemia; Male; Pancytopenia; Recurrence; Remission Induction | 2003 |
[Enhanced apoptosis-inducing effect of etoposide on leukemic cell lines M-07e and TF-1 by the proteasome inhibitor Z-LLL-CHO].
Topics: Apoptosis; Cell Cycle; Cell Line, Tumor; Cysteine Endopeptidases; Etoposide; Humans; Leukemia; Multienzyme Complexes; Oligopeptides; Proteasome Endopeptidase Complex; Proto-Oncogene Proteins c-bcl-2 | 2003 |
Dual role of NF-kappaB in apoptosis of THP-1 cells during treatment with etoposide and lipopolysaccharide.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; bcl-2-Associated X Protein; Caspase Inhibitors; Caspases; Cycloheximide; Dactinomycin; Drug Therapy, Combination; Enzyme Inhibitors; Etoposide; Humans; Inhibitor of Apoptosis Proteins; Leukemia; Lipopolysaccharides; NF-kappa B; Protein Synthesis Inhibitors; Proteins; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Tosyllysine Chloromethyl Ketone; Tumor Cells, Cultured; X-Linked Inhibitor of Apoptosis Protein | 2004 |
Etoposide induces chimeric Mll gene fusions.
Topics: Animals; Antineoplastic Agents, Phytogenic; Artificial Gene Fusion; DNA-Binding Proteins; Enzyme Inhibitors; Etoposide; Histone-Lysine N-Methyltransferase; Humans; Leukemia; Mice; Myeloid-Lymphoid Leukemia Protein; Oncogene Proteins, Fusion; Proto-Oncogenes; Topoisomerase II Inhibitors; Transcription Factors | 2004 |
Increased calcium influx and ribosomal content correlate with resistance to endoplasmic reticulum stress-induced cell death in mutant leukemia cell lines.
Topics: Anti-Bacterial Agents; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Area Under Curve; Calcium; Cell Death; Cell Line, Tumor; Cycloheximide; Dithiothreitol; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Neoplasm; Econazole; Endoplasmic Reticulum; Endoplasmic Reticulum Chaperone BiP; Etoposide; Fas Ligand Protein; Flow Cytometry; HL-60 Cells; Humans; Leukemia; Membrane Glycoproteins; Oligonucleotide Array Sequence Analysis; Phenotype; Ribosomes; Thapsigargin; Time Factors; Tunicamycin | 2004 |
[Synergistic effect of Apo2L and chemotherapeutic agents on leukemia cells].
Topics: Antineoplastic Agents; Apoptosis Regulatory Proteins; Cytarabine; Drug Synergism; Etoposide; Female; HL-60 Cells; Humans; Leukemia; Male; Membrane Glycoproteins; Receptors, TNF-Related Apoptosis-Inducing Ligand; Receptors, Tumor Necrosis Factor; TNF-Related Apoptosis-Inducing Ligand; Tumor Necrosis Factor-alpha | 2003 |
Recombination at chromosomal sequences involved in leukaemogenic rearrangements is differentially regulated by p53.
Topics: Animals; Baculoviridae; Cell Line; Chromosomes; Cloning, Molecular; COS Cells; DNA; Down-Regulation; Enzyme Inhibitors; Etoposide; Gene Deletion; Gene Expression Regulation, Neoplastic; Genes, p53; Humans; Leukemia; Models, Genetic; Mutation; Phenotype; Receptors, Retinoic Acid; Recombination, Genetic; Retinoic Acid Receptor alpha; Time Factors; Translocation, Genetic; Tumor Suppressor Protein p53 | 2004 |
Tailored therapy of adult acute leukaemia in Jehovah's Witnesses: unjustified reluctance to treat.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Case Management; Cytarabine; Daunorubicin; Etoposide; Female; Hemoglobins; Hemorrhage; Humans; Jehovah's Witnesses; Leukemia; Male; Middle Aged; Multiple Organ Failure; Patient Acceptance of Health Care; Refusal to Treat; Remission Induction; Tretinoin; Vincristine | 2004 |
Decreased nucleotide excision repair activity and alterations of topoisomerase IIalpha are associated with the in vivo resistance of a P388 leukemia subline to F11782, a novel catalytic inhibitor of topoisomerases I and II.
Topics: Animals; Antigens, Neoplasm; Antineoplastic Agents; Blotting, Northern; Catalysis; Cell Line, Tumor; Cisplatin; DNA Repair; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA-Binding Proteins; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Leukemia; Mice; Mice, Inbred DBA; Mutation, Missense; Naphthalenes; Neoplasm Transplantation; Neoplasms, Experimental; Organophosphorus Compounds; Pyrans; RNA, Messenger; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 2004 |
Selective induction of apoptosis by the pyrrolo-1,5-benzoxazepine 7-[[dimethylcarbamoyl]oxy]-6-(2-naphthyl)pyrrolo-[2,1-d] (1,5)-benzoxazepine (PBOX-6) in Leukemia cells occurs via the c-Jun NH2-terminal kinase-dependent phosphorylation and inactivation o
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; bcl-X Protein; Carbazoles; Dactinomycin; Drug Resistance, Neoplasm; Etoposide; Humans; Indoles; JNK Mitogen-Activated Protein Kinases; Jurkat Cells; K562 Cells; Leukemia; Leukocytes, Mononuclear; Mitogen-Activated Protein Kinases; Oxazepines; Phosphorylation; Proto-Oncogene Mas; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Subcellular Fractions; Tumor Cells, Cultured; Ultraviolet Rays | 2004 |
Secondary leukemias in refractory germ cell tumor patients undergoing autologous stem-cell transplantation using high-dose etoposide.
Topics: Adolescent; Adult; Antineoplastic Agents, Phytogenic; Carboplatin; Combined Modality Therapy; Etoposide; Germinoma; Humans; Incidence; Indiana; Leukemia; Male; Middle Aged; Prostatic Neoplasms; Retrospective Studies; Salvage Therapy; Stem Cell Transplantation; Transplantation, Autologous | 2004 |
Identification of deficient mitochondrial signaling in apoptosis resistant leukemia cells by flow cytometric analysis of intracellular cytochrome c, caspase-3 and apoptosis.
Topics: Antibodies, Monoclonal; Apoptosis; Blotting, Western; Caspase 3; Caspases; Cell Membrane Permeability; Cyclophosphamide; Cytochromes c; Drug Resistance, Neoplasm; Etoposide; fas Receptor; Flow Cytometry; Humans; Jurkat Cells; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid; Microscopy, Fluorescence; Mitochondria; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; Transfection | 2004 |
In vitro and in vivo evaluation of the influence of type III NaPi co-transporter activity during apoptosis on 99mTc-(V)DMSA uptake in the human leukaemic cell line U937.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Dose-Response Relationship, Drug; Etoposide; Humans; Leukemia; Metabolic Clearance Rate; Mice; Mice, Nude; Organ Specificity; Radionuclide Imaging; Radiopharmaceuticals; Sodium-Phosphate Cotransporter Proteins; Symporters; Technetium Tc 99m Dimercaptosuccinic Acid; Tissue Distribution | 2004 |
Transcriptional and post-transcriptional regulation of the PKC delta gene by etoposide in L1210 murine leukemia cells: implication of PKC delta autoregulation.
Topics: Acetophenones; Adenoviridae; Animals; Antineoplastic Agents; Benzopyrans; Blotting, Western; Cell Fractionation; Cell Line, Tumor; Enzyme Inhibitors; Etoposide; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Leukemic; Leukemia; Mice; Models, Biological; Protein Kinase C; Protein Kinase C-delta; RNA, Messenger; Transcription, Genetic; Up-Regulation | 2004 |
Novel 2'-substituted, 3'-deoxy-phosphatidyl-myo-inositol analogues reduce drug resistance in human leukaemia cell lines with an activated phosphoinositide 3-kinase/Akt pathway.
Topics: Antineoplastic Agents; Apoptosis; Cell Survival; Cytarabine; Down-Regulation; Drug Resistance, Neoplasm; Enzyme Inhibitors; Etoposide; Humans; Leukemia; Neoplasm Proteins; Phosphatidylinositol 3-Kinases; Phosphatidylinositols; Phosphoinositide-3 Kinase Inhibitors; Phospholipid Ethers; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Tumor Cells, Cultured | 2004 |
PI-3-kinase/NF-kappaB mediated response of Jurkat T leukemic cells to two different chemotherapeutic drugs, etoposide and TRAIL.
Topics: Antineoplastic Agents; Apoptosis Regulatory Proteins; Caspase 3; Caspases; Cell Death; Enzyme Activation; Etoposide; Flow Cytometry; Gene Expression Regulation; Humans; I-kappa B Kinase; Immunohistochemistry; Jurkat Cells; Leukemia; Membrane Glycoproteins; NF-kappa B; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; TNF-Related Apoptosis-Inducing Ligand; Transcription Factor RelA; Tumor Necrosis Factor-alpha | 2004 |
[GM-CSF regulates the Vp16 induced leukemic cell apoptosis].
Topics: Apoptosis; Etoposide; Flow Cytometry; Granulocyte-Macrophage Colony-Stimulating Factor; HL-60 Cells; Humans; Leukemia | 1997 |
Camptothecin- and etoposide-induced apoptosis in human leukemia cells is independent of cell death receptor-3 and -4 aggregation but accelerates tumor necrosis factor-related apoptosis-inducing ligand-mediated cell death.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Camptothecin; CASP8 and FADD-Like Apoptosis Regulating Protein; Etoposide; Fas-Associated Death Domain Protein; Gene Deletion; Genes, Dominant; HL-60 Cells; Humans; Intracellular Signaling Peptides and Proteins; Leukemia; Ligands; Membrane Glycoproteins; Receptors, TNF-Related Apoptosis-Inducing Ligand; Receptors, Tumor Necrosis Factor; Receptors, Tumor Necrosis Factor, Member 25; TNF-Related Apoptosis-Inducing Ligand; Transfection; Tumor Necrosis Factor Ligand Superfamily Member 15; Tumor Necrosis Factor Receptor-Associated Peptides and Proteins; Tumor Necrosis Factor-alpha; TWEAK Receptor; U937 Cells | 2004 |
Hematopoietic cytokines enhance Chk1-dependent G2/M checkpoint activation by etoposide through the Akt/GSK3 pathway to inhibit apoptosis.
Topics: Animals; Apoptosis; Cell Cycle; Cell Division; Cell Line; Cell Line, Tumor; Checkpoint Kinase 1; Cytokines; Erythropoietin; Etoposide; Flow Cytometry; G2 Phase; Glycogen Synthase Kinase 3; Humans; Interleukin-3; Leukemia; Mice; Phosphorylation; Phosphotyrosine; Protein Kinases; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt | 2005 |
p21 (Waf1/Cip1) and FasL gene activation via Sp1 and NFkappaB is required for leukemia cell survival but not for cell death induced by diverse stimuli.
Topics: Apoptosis; Base Sequence; Binding Sites; Cell Cycle Proteins; Cell Line, Tumor; Cell Survival; Cyclin-Dependent Kinase Inhibitor p21; DNA Primers; Etoposide; Fas Ligand Protein; Humans; Leukemia; Membrane Glycoproteins; NF-kappa B; Promoter Regions, Genetic; Sp1 Transcription Factor | 2005 |
High cumulative rate of secondary leukemia after continuous etoposide treatment for solid tumors in children and young adults.
Topics: Adolescent; Antineoplastic Agents, Phytogenic; Case-Control Studies; Child; Child, Preschool; Drug Administration Schedule; Etoposide; Female; Follow-Up Studies; France; Humans; Incidence; Infant; Leukemia; Male; Neoplasms; Neoplasms, Second Primary; Palliative Care; Survival Rate | 2005 |
Knee arthritis as a rare inaugural manifestation of adult leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Arthritis; Cytarabine; Diagnosis, Differential; Dose-Response Relationship, Drug; Etoposide; Humans; Knee Joint; Leukemia; Magnetic Resonance Imaging; Male; Mitoxantrone; Radiography; Remission Induction; Treatment Outcome | 2005 |
Deguelin, A PI3K/AKT inhibitor, enhances chemosensitivity of leukaemia cells with an active PI3K/AKT pathway.
Topics: Acute Disease; Antigens, CD34; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cells, Cultured; Cytarabine; Drug Resistance, Neoplasm; Erythropoietin; Etoposide; HL-60 Cells; Humans; Leukemia; Leukemia, Myeloid; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Rotenone; Signal Transduction; Stem Cell Factor; Stem Cells | 2005 |
Highly active antiretroviral therapy and outcome of AIDS-related Burkitt's lymphoma or leukemia. Results of the PETHEMA-LAL3/97 study.
Topics: Acquired Immunodeficiency Syndrome; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Active; Cyclophosphamide; Cytarabine; Dexamethasone; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Humans; Ifosfamide; Leucovorin; Leukemia; Lymphoma, AIDS-Related; Male; Methotrexate; Middle Aged; Prednisone; Treatment Outcome; Vincristine | 2005 |
Adenovirus-mediated human topoisomerase IIalpha gene transfer increases the sensitivity of etoposide-resistant human and mouse breast cancer cells.
Topics: Adenoviridae; Animals; Antigens, Neoplasm; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; DNA Topoisomerases, Type II; DNA-Binding Proteins; Drug Resistance, Neoplasm; Etoposide; Female; Gene Expression Regulation, Enzymologic; Gene Transfer Techniques; Genetic Vectors; Humans; Isoenzymes; Leukemia; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Inbred Strains; RNA, Messenger; Transduction, Genetic; Tumor Burden | 2005 |
Usefulness of PKH fluorescent labelling to study leukemic cell proliferation with various cytostatic drugs or acetyl tetrapeptide--AcSDKP.
Topics: Amsacrine; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Bromodeoxyuridine; Cell Proliferation; Cytarabine; Daunorubicin; DNA; Etoposide; Flow Cytometry; Fluorescent Dyes; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Hydrocarbons, Chlorinated; Leukemia; Leukemia, Myeloid, Acute; Microscopy, Fluorescence; Oligopeptides; Organic Chemicals; Radiation-Protective Agents | 2005 |
MLL rearrangements are induced by low doses of etoposide in human fetal hematopoietic stem cells.
Topics: Antineoplastic Agents, Phytogenic; Cell Culture Techniques; Cell Cycle; Cell Survival; DNA Damage; Dose-Response Relationship, Drug; Etoposide; Female; Fetus; Gene Rearrangement; Hematopoietic Stem Cells; Histone-Lysine N-Methyltransferase; Humans; Leukemia; Maternal-Fetal Exchange; Myeloid-Lymphoid Leukemia Protein; Pregnancy | 2006 |
Influence of galangin on HL-60 cell proliferation and survival.
Topics: Antineoplastic Agents, Phytogenic; Caspase 3; Cell Cycle; Cell Differentiation; Cell Membrane; Cell Proliferation; Cell Size; Cell Survival; Dimethyl Sulfoxide; DNA Fragmentation; DNA, Neoplasm; Dose-Response Relationship, Drug; Etoposide; Flavonoids; Flow Cytometry; HL-60 Cells; Humans; Leukemia; Mutagens; Nucleosomes; Phosphatidylserines; Reactive Oxygen Species | 2006 |
Early stem cell transplantation for refractory acute leukemia after salvage therapy with high-dose etoposide and cyclophosphamide.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Cyclophosphamide; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Humans; Leukemia; Male; Middle Aged; Remission Induction; Retrospective Studies; Salvage Therapy; Stem Cell Transplantation; Survival Rate | 2006 |
Antileukemic roles of human phospholipid scramblase 1 gene, evidence from inducible PLSCR1-expressing leukemic cells.
Topics: Apoptosis; Cell Cycle; Cell Differentiation; Cell Line; Cell Proliferation; Etoposide; G1 Phase; Gene Expression Regulation; Gene Expression Regulation, Leukemic; Humans; Leukemia; Myeloid Cells; Phospholipid Transfer Proteins; Transfection; Tumor Cells, Cultured; U937 Cells | 2006 |
[Influence of chemotherapy on expression of TRAIL in primary acute leukemic cells].
Topics: Acute Disease; Antineoplastic Agents; Bone Marrow Cells; Etoposide; Humans; Interferon-alpha; Leukemia; TNF-Related Apoptosis-Inducing Ligand; Tumor Cells, Cultured | 2006 |
Cytotoxic effects of histone deacetylase inhibitor FK228 (depsipeptide, formally named FR901228) in combination with conventional anti-leukemia/lymphoma agents against human leukemia/lymphoma cell lines.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Camptothecin; Carboplatin; Cell Line, Tumor; Cell Survival; Cyclophosphamide; Cytarabine; Depsipeptides; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Etoposide; Histone Deacetylase Inhibitors; HL-60 Cells; Humans; Imatinib Mesylate; Irinotecan; K562 Cells; Leukemia; Lymphoma; Mercaptopurine; Piperazines; Pyrimidines; Time Factors | 2007 |
Zygomycosis in the immunocompromised patient: a case report.
Topics: Absidia; Acute Disease; Aerosols; Amphotericin B; Amsacrine; Antibiotic Prophylaxis; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Daunorubicin; Debridement; Drug Resistance, Fungal; Drug Resistance, Neoplasm; Etoposide; Fluconazole; Humans; Immunocompromised Host; Leukemia; Liposomes; Middle Aged; Mucormycosis; Sinusitis; Tomography, X-Ray Computed | 2006 |
Overexpression of sorcin in multidrug resistant human leukemia cells and its role in regulating cell apoptosis.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; bcl-2-Associated X Protein; Calcium-Binding Proteins; Cell Line, Tumor; Cytosol; Electrophoresis, Gel, Two-Dimensional; Etoposide; Gene Expression Regulation, Neoplastic; Humans; K562 Cells; Leukemia; Proteomics; Proto-Oncogene Proteins c-bcl-2 | 2006 |
Chemotherapy-related secondary leukemias: A role for DNA repair by error-prone non-homologous end joining in topoisomerase II - Induced chromosomal rearrangements.
Topics: Antineoplastic Agents, Phytogenic; Chromatin Immunoprecipitation; Chromosome Aberrations; Chromosome Breakage; Core Binding Factor Alpha 2 Subunit; DNA Breaks, Double-Stranded; DNA Repair; DNA Topoisomerases, Type II; Drug-Related Side Effects and Adverse Reactions; Etoposide; Humans; Jurkat Cells; Leukemia; Neoplasms; Protein Binding; Rad52 DNA Repair and Recombination Protein; Recombination, Genetic; Topoisomerase II Inhibitors | 2007 |
Divergent cytotoxic effects of PKC412 in combination with conventional antileukemic agents in FLT3 mutation-positive versus -negative leukemia cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Cell Line, Tumor; Cytarabine; Doxorubicin; Etoposide; fms-Like Tyrosine Kinase 3; Humans; Idarubicin; Leukemia; Methotrexate; Mitoxantrone; Mutation; Protein Kinase C; Staurosporine | 2007 |
Synergism between etoposide and 17-AAG in leukemia cells: critical roles for Hsp90, FLT3, topoisomerase II, Chk1, and Rad51.
Topics: Antineoplastic Agents; Benzoquinones; Blotting, Western; Cell Line, Tumor; Checkpoint Kinase 1; DNA Repair Enzymes; DNA Topoisomerases, Type II; Drug Synergism; Etoposide; fms-Like Tyrosine Kinase 3; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Leukemia; Protein Kinases; Rad51 Recombinase; RNA, Small Interfering | 2007 |
CODOX-M/IVAC (NCI 89-C-41) in children and adolescents with Burkitt's leukemia/lymphoma and large B-cell lymphomas: a 15-year monocentric experience.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Female; Humans; Ifosfamide; Leukemia; Lymphoma, Large B-Cell, Diffuse; Male; Methotrexate; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Risk Factors; Survival Rate; Treatment Outcome; Vincristine | 2007 |
Dietary flavonoids induce MLL translocations in primary human CD34+ cells.
Topics: Antigens, CD34; Cells, Cultured; Dietary Supplements; DNA Breaks, Double-Stranded; Etoposide; Flavonoids; Genistein; Histone-Lysine N-Methyltransferase; Humans; Kaempferols; Leukemia; Leukocytes, Mononuclear; Myeloid-Lymphoid Leukemia Protein; Quercetin; Translocation, Genetic | 2007 |
The role of cordycepin in cancer treatment via induction or inhibition of apoptosis: implication of polyadenylation in a cell type specific manner.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Caspase 6; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Deoxyadenosines; DNA Fragmentation; Etoposide; Flow Cytometry; Fluorescent Dyes; Humans; Image Processing, Computer-Assisted; Indoles; Leukemia; Membrane Potentials; Mitochondrial Membranes; Neoplasms; Poly A | 2008 |
Genome scan implicates adhesion biological pathways in secondary leukemia.
Topics: Adolescent; Case-Control Studies; Cell Adhesion; Child; Child, Preschool; Cohort Studies; Etoposide; Female; Gene Frequency; Genome, Human; Humans; Infant; Leukemia; Loss of Heterozygosity; Male; Polymorphism, Single Nucleotide; Translocation, Genetic | 2007 |
Long-term follow-up of busulfan, etoposide, and nimustine hydrochloride (ACNU) or melphalan as conditioning regimens for childhood acute leukemia and lymphoma.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Humans; Infant; Leukemia; Lymphoma; Lymphoma, Non-Hodgkin; Male; Melphalan; Nimustine; Recurrence; Retrospective Studies; Stem Cell Transplantation; Survival Rate; Transplantation Conditioning; Transplantation, Homologous | 2007 |
Genotoxic stress-induced expression of p53 and apoptosis in leukemic clam hemocytes with cytoplasmically sequestered p53.
Topics: Amino Acid Sequence; Animals; Apoptosis; DNA Damage; Etoposide; Fatty Acids, Unsaturated; Hemocytes; Humans; Leukemia; Mitoxantrone; Molecular Sequence Data; Mya; Topoisomerase II Inhibitors; Tumor Suppressor Protein p53 | 2008 |
Ornithine decarboxylase attenuates leukemic chemotherapy drugs-induced cell apoptosis and arrest in human promyelocytic HL-60 cells.
Topics: Acetylcysteine; Antineoplastic Agents; Apoptosis; Caspases; Cell Cycle; Cisplatin; Etoposide; Glutathione; HL-60 Cells; Humans; Leukemia; Membrane Potential, Mitochondrial; Ornithine Decarboxylase; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Putrescine; Reactive Oxygen Species | 2008 |
Clinical and cell kinetic studies of the effects of the epipodophyllotoxin VP16-213 during therapy of refractory acute nonlymphocytic leukemia.
Topics: Acute Disease; Adolescent; Adult; Azacitidine; Cell Division; Child; Child, Preschool; DNA, Neoplasm; Drug Resistance; Etoposide; Female; Flow Cytometry; Humans; Infant; Kinetics; Leukemia; Male; Mitosis; Podophyllotoxin | 1982 |
Single-agent and combination chemotherapy with etoposide in the acute leukemias of childhood.
Topics: Acute Disease; Azacitidine; Child; Drug Therapy, Combination; Etoposide; Humans; Leukemia; Podophyllotoxin; Prednisone; Vincristine | 1982 |
Pharmacokinetics of etoposide (VP16) in children and adolescents with refractory solid tumors.
Topics: Adolescent; Adult; Child; Child, Preschool; Cisplatin; Etoposide; Female; Humans; Kinetics; Leukemia; Male; Metabolic Clearance Rate; Neoplasms; Podophyllotoxin | 1984 |
[VP 16-213 in the treatment of acute leukemia in childhood].
Topics: Acute Disease; Adolescent; Antineoplastic Agents; Child; Child, Preschool; Cytarabine; Doxorubicin; Drug Therapy, Combination; Etoposide; Female; Humans; Leukemia; Leukemia, Lymphoid; Male; Podophyllotoxin | 1983 |
Pharmacokinetics of Teniposide (VM26) and etoposide (VP16-213) in children with cancer.
Topics: Biotransformation; Child; Chromatography, High Pressure Liquid; Etoposide; Humans; Kinetics; Leukemia; Models, Biological; Neoplasms; Podophyllotoxin; Teniposide | 1982 |
Etoposide in the treatment of acute leukemia in adults.
Topics: Acute Disease; Adult; Drug Administration Schedule; Drug Therapy, Combination; Etoposide; Humans; Leukemia; Podophyllotoxin | 1982 |
Hypophosphorylation of topoisomerase II in etoposide (VP-16)-resistant human leukemia K562 cells associated with reduced levels of beta II protein kinase C.
Topics: Antineoplastic Agents, Phytogenic; DNA; DNA Damage; DNA Topoisomerases, Type II; Drug Resistance; Etoposide; Humans; Leukemia; Phosphorylation; Protein Kinase C; Tumor Cells, Cultured | 1995 |
Evaluation of the cytotoxic activity of gemcitabine in primary cultures of tumor cells from patients with hematologic or solid tumors.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Cisplatin; Cladribine; Colorectal Neoplasms; Cytarabine; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Etoposide; Female; Gemcitabine; Humans; In Vitro Techniques; Leukemia; Lung Neoplasms; Lymphoma; Ribonucleotide Reductases; Tumor Cells, Cultured; Urogenital Neoplasms | 1995 |
[Successful collection of peripheral blood stem cells mobilized by a combination of G-CSF with high-dose Ara-C or high-dose etoposide].
Topics: Acute Disease; Adolescent; Adult; Blood Component Removal; Cytarabine; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Lymphoma, Non-Hodgkin; Male; Middle Aged | 1993 |
A new flow cytometric method for discrimination of apoptotic cells and detection of their cell cycle specificity through staining of F-actin and DNA.
Topics: Actins; Apoptosis; Cell Cycle; Cycloheximide; Dactinomycin; DNA, Neoplasm; Etoposide; Evaluation Studies as Topic; Flow Cytometry; Humans; Leukemia; Microscopy, Confocal; Phalloidine; Propidium; Staining and Labeling; Tumor Cells, Cultured | 1995 |
Further characterisation of the in situ terminal deoxynucleotidyl transferase (TdT) assay for the flow cytometric analysis of apoptosis in drug resistant and drug sensitive leukaemic cells.
Topics: Abelson murine leukemia virus; Antineoplastic Agents; Apoptosis; Cell Nucleus; DNA Damage; DNA Nucleotidylexotransferase; DNA, Neoplasm; Drug Resistance, Neoplasm; Etoposide; Flow Cytometry; HL-60 Cells; Humans; Hydroxyurea; Leukemia; Melphalan; Oncogene Proteins v-abl; Protein-Tyrosine Kinases; Recombinant Proteins; Tumor Cells, Cultured | 1995 |
The role of cell cycle regulation and apoptosis triggering in determining the sensitivity of leukemic cells to topoisomerase I and II inhibitors.
Topics: Apoptosis; Base Sequence; Camptothecin; Cell Cycle; Cell Line; Cell Survival; DNA Damage; DNA Primers; DNA, Neoplasm; Dose-Response Relationship, Drug; Etoposide; Humans; Leukemia; Microscopy, Electron; Molecular Sequence Data; Polymerase Chain Reaction; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 1995 |
Extramedullary toxicity of a conditioning regimen containing busulphan, cyclophosphamide and etoposide in 84 patients undergoing autologous and allogenic bone marrow transplantation.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Marrow Transplantation; Busulfan; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Graft vs Host Disease; Humans; Leukemia; Lung; Lymphoma; Male; Middle Aged; Recurrence; Skin; Survival Rate; Transplantation, Autologous; Transplantation, Homologous | 1995 |
Risk of secondary leukemia following high cumulative doses of etoposide during chemotherapy for testicular cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Etoposide; Humans; Leukemia; Male; Neoplasms, Second Primary; Testicular Neoplasms | 1995 |
Secondary leukemia associated with a conventional dose of etoposide: review of serial germ cell tumor protocols.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 4; Cisplatin; Clinical Trials as Topic; Etoposide; Humans; Leukemia; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Male; Neoplasms, Germ Cell and Embryonal; Neoplasms, Second Primary; Retrospective Studies; Salvage Therapy; Testicular Neoplasms; Translocation, Genetic | 1993 |
ALL-1 gene rearrangements in DNA topoisomerase II inhibitor-related leukemia in children.
Topics: Acute Disease; Adolescent; Bone Marrow Transplantation; Child; Child, Preschool; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 11; Combined Modality Therapy; Dactinomycin; DNA-Binding Proteins; Etoposide; Female; Genes; Histone-Lysine N-Methyltransferase; Humans; Infant; Leukemia; Leukemia, Myeloid; Leukemia, Radiation-Induced; Male; Myelodysplastic Syndromes; Myeloid-Lymphoid Leukemia Protein; Neoplasm Proteins; Neoplasms; Neoplasms, Second Primary; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Proto-Oncogenes; Radiotherapy; Teniposide; Topoisomerase II Inhibitors; Transcription Factors; Translocation, Genetic; Whole-Body Irradiation | 1995 |
Collection and transplantation of peripheral blood stem cells in very small children weighting 20 kg or less.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blood Component Removal; Blood Preservation; Body Weight; Bone Marrow Diseases; Carboplatin; Catheterization, Central Venous; Catheters, Indwelling; Child, Preschool; Cisplatin; Colony-Forming Units Assay; Combined Modality Therapy; Contraindications; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Female; Graft Survival; Hematopoietic Stem Cell Transplantation; Humans; Infant; Leukemia; Male; Neoplasms; Platelet Transfusion; Retrospective Studies; Safety | 1995 |
[Therapeutic effects of peripheral blood stem cell transplantation following combination chemotherapy using ranimustine, cytarabine, etoposide and cyclophosphamide for patients with hematological malignancies].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Lymphoma; Male; Middle Aged; Nitrosourea Compounds | 1994 |
Differential induction of etoposide-mediated apoptosis in human leukemia HL-60 and K562 cells.
Topics: Apoptosis; Cell Nucleus; DNA; DNA Damage; Etoposide; Flow Cytometry; Gene Expression Regulation; Genes, fos; Genes, jun; Humans; Leukemia; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured | 1994 |
Drug-sensitivity and DNA-binding of a subform of topoisomerase II alpha in resistant human HL-60 cells.
Topics: Amsacrine; Antigens, Neoplasm; Antineoplastic Agents; DNA Topoisomerases, Type II; DNA-Binding Proteins; DNA, Neoplasm; Drug Resistance; Etoposide; Humans; Isoenzymes; Leukemia; Tumor Cells, Cultured; Vanadates | 1994 |
Quantification of topoisomerase-DNA complexes in leukemia cells from patients undergoing therapy with a topoisomerase-directed agent.
Topics: Amsacrine; Antineoplastic Agents; Camptothecin; DNA Probes; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA, Neoplasm; Drug Resistance; Etoposide; Humans; Immunoblotting; Leukemia; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan; Tumor Cells, Cultured | 1994 |
Reduced phosphorylation of topoisomerase II in etoposide-resistant human leukemia K562 cells.
Topics: Adenosine Triphosphate; Base Sequence; DNA Topoisomerases, Type II; DNA, Complementary; DNA, Neoplasm; Drug Resistance; Etoposide; Humans; Leukemia; Molecular Sequence Data; Nuclear Proteins; Phosphorylation; Polymorphism, Genetic; Sequence Analysis, DNA; Tumor Cells, Cultured | 1994 |
Etoposide, cyclophosphamide, total-body irradiation, and allogeneic bone marrow transplantation for hematologic malignancies.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Hemorrhage; Humans; Leukemia; Lung Diseases; Lymphoma; Male; Middle Aged; Recurrence; Survival Rate; Transplantation, Homologous; Whole-Body Irradiation | 1994 |
21-day schedule oral etoposide in children--a feasibility study.
Topics: Administration, Oral; Adolescent; Child; Child, Preschool; Drug Administration Schedule; Etoposide; Feasibility Studies; Female; Humans; Leukemia; Leukopenia; Male; Neuroblastoma; Neutropenia; Sarcoma; Thrombocytopenia; Treatment Outcome | 1993 |
[Neutropenic typhlitis: a frequently missed complication of aplasia-inducing tumor therapy with a possible association to the combination of etoposide with high-dose cytosine-arabinoside].
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Synergism; Enterocolitis, Pseudomembranous; Etoposide; Female; Humans; Leukemia; Male; Neutropenia; Retrospective Studies | 1994 |
Tyrosinase-induced phenoxyl radicals of etoposide (VP-16): interaction with reductants in model systems, K562 leukemic cell and nuclear homogenates.
Topics: Ascorbic Acid; Cell Nucleus; Chromatography, High Pressure Liquid; Deferoxamine; Electron Spin Resonance Spectroscopy; Etoposide; Free Radicals; Glutathione; Humans; Leukemia; Monophenol Monooxygenase; Oxidation-Reduction; Phenols; Thioctic Acid; Tumor Cells, Cultured | 1993 |
Etoposide in combination with cyclophosphamide and total body irradiation or busulfan as conditioning for marrow transplantation in adults and children.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cyclophosphamide; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Infant; Leukemia; Lung Diseases, Interstitial; Lymphoma; Male; Middle Aged; Retrospective Studies; Skin Diseases; Whole-Body Irradiation | 1994 |
Altered gene expression in human leukemia K562 cells selected for resistance to etoposide.
Topics: DNA Topoisomerases, Type II; Drug Resistance; Etoposide; Gene Expression; Humans; Leukemia; RNA, Messenger; Transcription, Genetic; Tumor Cells, Cultured | 1993 |
Phorbol regulation of topoisomerases I and II in human leukemia cells. Studies in an additional cell pair sensitive or resistant to phorbol-induced differentiation.
Topics: Cell Differentiation; Cell Nucleus; Cell Survival; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Etoposide; Gene Expression Regulation, Enzymologic; Humans; Leukemia; Phorbol Esters; Tissue Extracts; Tumor Cells, Cultured | 1994 |
Novel selection and genetic characterisation of an etoposide-resistant human leukaemic CCRF-CEM cell line.
Topics: Base Sequence; Chromosome Banding; Chromosomes, Human, Pair 20; Chromosomes, Human, Pair 3; Codon; DNA Topoisomerases, Type II; DNA, Neoplasm; Drug Resistance; Etoposide; Humans; Karyotyping; Leukemia; Molecular Sequence Data; Mutation; Phenotype; Polymerase Chain Reaction; Sequence Analysis, DNA; Tumor Cells, Cultured | 1993 |
Role of total body irradiation as based on the comparison of preparation regimens for allogeneic bone marrow transplantation for acute leukemia in first complete remission.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Etoposide; Female; Humans; Infant; Japan; Leukemia; Male; Methotrexate; Nimustine; Proportional Hazards Models; Radiotherapy Dosage; Remission Induction; Transplantation, Homologous; Whole-Body Irradiation | 1993 |
Growth and growth hormone secretion after bone marrow transplantation.
Topics: Bone Marrow Transplantation; Child; Child, Preschool; Clinical Protocols; Cyclophosphamide; Etoposide; Female; Growth; Growth Disorders; Growth Hormone; Humans; Infant; Insulin-Like Growth Factor I; Leukemia; Male; Melphalan; Radiotherapy Dosage; Whole-Body Irradiation | 1993 |
Hematopoietic growth factors after HLA-identical allogeneic bone marrow transplantation in patients treated with methotrexate-containing graft-vs.-host disease prophylaxis.
Topics: Adult; Aged; Bone Marrow Transplantation; Cyclophosphamide; Etoposide; Female; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Histocompatibility; Humans; Leukemia; Male; Methotrexate; Middle Aged; Recombinant Proteins; Recurrence; Survival Rate; Transplantation, Homologous; Treatment Outcome; Whole-Body Irradiation | 1995 |
Pneumocystis carinii pneumonia in adults with acute leukaemia: is there a need for primary chemoprophylaxis?
Topics: Aclarubicin; Acute Disease; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cohort Studies; Cyclophosphamide; Cytarabine; Daunorubicin; Dexamethasone; Etoposide; Female; Finland; Humans; Immunocompromised Host; Incidence; Leukemia; Male; Mercaptopurine; Methotrexate; Middle Aged; Mitoxantrone; Pneumonia, Pneumocystis; Prednisone; Premedication; Retrospective Studies; Thioguanine; Trimethoprim, Sulfamethoxazole Drug Combination; Vincristine | 1996 |
Reversal effect of itraconazole on adriamycin and etoposide resistance in human leukemia cells.
Topics: Antibiotics, Antineoplastic; Antifungal Agents; Antineoplastic Agents, Phytogenic; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Gene Expression Regulation, Neoplastic; Humans; Itraconazole; Leukemia; Tumor Cells, Cultured | 1996 |
Distribution of 11q23 breakpoints within the MLL breakpoint cluster region in de novo acute leukemia and in treatment-related acute myeloid leukemia: correlation with scaffold attachment regions and topoisomerase II consensus binding sites.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Agents, Phytogenic; Base Sequence; Binding Sites; Centromere; Child; Child, Preschool; Chromatin; Chromosomes, Human, Pair 11; Consensus Sequence; DNA Topoisomerases, Type II; DNA-Binding Proteins; DNA, Neoplasm; Etoposide; Female; Histone-Lysine N-Methyltransferase; Humans; Infant; Leukemia; Male; Middle Aged; Molecular Sequence Data; Myeloid-Lymphoid Leukemia Protein; Neoplasms, Second Primary; Proto-Oncogenes; Telomere; Teniposide; Topoisomerase II Inhibitors; Transcription Factors; Translocation, Genetic; Tumor Cells, Cultured | 1996 |
[Apoptosis of human leukemic cells induced by topoisomerase I and II inhibitors].
Topics: Alkaloids; Apoptosis; Camptothecin; Cell Cycle; Cell Differentiation; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA, Neoplasm; Etoposide; Humans; Leukemia; Protein Kinase C; Signal Transduction; Staurosporine; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 1996 |
High-dose carmustine, etoposide and melphalan ('BEM') with autologous stem cell transplantation: a dose-toxicity study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Dose-Response Relationship, Drug; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Liver Function Tests; Lymphoma; Male; Melphalan; Middle Aged; Multiple Myeloma; Respiratory Function Tests; Retrospective Studies; Transplantation, Autologous | 1996 |
[Effects of carboplatin combination with etoposide against leukemia/lymphoma cell lines].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Synergism; Etoposide; Humans; Leukemia; Lymphoma; Tumor Cells, Cultured | 1996 |
[Modulation of bcl-2 antisense RNA on programmed cell death of leukemic cell line].
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Etoposide; Gene Expression Regulation, Neoplastic; Humans; Leukemia; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; RNA, Antisense; Tumor Cells, Cultured | 1996 |
Collateral sensitivity to the bisdioxopiperazine dexrazoxane (ICRF-187) in etoposide (VP-16)-resistant human leukemia K562 cells.
Topics: Alkenes; Dose-Response Relationship, Drug; Enzyme Inhibitors; Etoposide; Humans; Leukemia; Polyenes; Pyrones; Razoxane; Thiobarbiturates | 1996 |
Monoclonal antibody to single-stranded DNA is a specific and sensitive cellular marker of apoptosis.
Topics: Animals; Antibodies, Monoclonal; Apoptosis; Biomarkers; Cell Line; Cisplatin; DNA, Single-Stranded; Etoposide; Fluorescent Antibody Technique, Indirect; HL-60 Cells; Humans; Immunohistochemistry; Leukemia; Mice; Necrosis; Sensitivity and Specificity; Tumor Cells, Cultured | 1996 |
[CD7, HLA-DR, CD38 positive acute undifferentiated leukemia with subcutaneous tumor and thymoma].
Topics: Acute Disease; ADP-ribosyl Cyclase; ADP-ribosyl Cyclase 1; Antigens, CD; Antigens, CD7; Antigens, Differentiation; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Chromosome Disorders; Cytarabine; Etoposide; Gene Rearrangement; HLA-DR Antigens; Humans; Immunoglobulin Heavy Chains; Immunophenotyping; Leukemia; Membrane Glycoproteins; Mitoxantrone; N-Glycosyl Hydrolases; Prednisolone; Receptors, Antigen, T-Cell, gamma-delta; Remission Induction; Skin Neoplasms; Thymoma; Thymus Neoplasms | 1996 |
Endo-exonuclease of human leukaemic cells: evidence for a role in apoptosis.
Topics: Apoptosis; Cell Nucleus; Cytosol; DNA Fragmentation; Endonucleases; Endoplasmic Reticulum; Etoposide; Exonucleases; Humans; Kinetics; Leukemia; Molecular Weight; Podophyllotoxin; Tumor Cells, Cultured | 1996 |
Influence of graft-versus-host disease on outcome following allogeneic transplantation with radiation-free preparative therapy in patients with advanced leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Combined Modality Therapy; Cyclophosphamide; Etoposide; Graft vs Host Disease; Humans; Leukemia; Treatment Outcome | 1996 |
Relationship between cytotoxicity and site-specific DNA recombination after in vitro exposure of leukemia cells to etoposide.
Topics: Acute Disease; Antineoplastic Agents, Phytogenic; Base Sequence; DNA Primers; DNA, Neoplasm; Etoposide; Exons; Gene Rearrangement; Humans; Leukemia; Leukemia, Myeloid; Molecular Sequence Data; Neoplasms, Second Primary; Sequence Deletion; Time Factors; Tumor Cells, Cultured | 1996 |
Increased gadd153 messenger RNA level is associated with apoptosis in human leukemic cells treated with etoposide.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; CCAAT-Enhancer-Binding Proteins; Daunorubicin; DNA Fragmentation; DNA-Binding Proteins; Etoposide; HL-60 Cells; Humans; Leukemia; Nuclear Proteins; RNA, Messenger; Serine Proteinase Inhibitors; Transcription Factor CHOP; Transcription Factors; Tumor Cells, Cultured | 1997 |
Enhancement of etoposide (VP-16) cytotoxicity by enzymatic and photodynamically induced oxidative stress.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Buthionine Sulfoximine; Cytoplasm; DNA Damage; Drug Synergism; Electron Spin Resonance Spectroscopy; Etoposide; Free Radicals; Glutathione; Humans; Indoles; Leukemia; Organometallic Compounds; Oxidative Stress; Photosensitizing Agents; Tumor Cells, Cultured | 1997 |
Low levels of serum soluble c-kit relates to delayed engraftment after bone marrow transplantation.
Topics: Adolescent; Adult; Antineoplastic Agents, Phytogenic; Bone Marrow Transplantation; Cyclophosphamide; Etoposide; Graft Rejection; Graft vs Host Disease; Humans; Leukemia; Lymphoma; Proto-Oncogene Proteins c-kit; Transplantation Conditioning; Whole-Body Irradiation | 1997 |
Autologous bone marrow purging by in situ IL-2 activation of endogenous killer cells.
Topics: Bone Marrow Purging; Bone Marrow Transplantation; Breast Neoplasms; Colony-Forming Units Assay; Cytarabine; Cytotoxicity, Immunologic; Daunorubicin; Drug Resistance, Neoplasm; Etoposide; Female; Hematopoietic Stem Cells; HL-60 Cells; Humans; Interleukin-2; Killer Cells, Lymphokine-Activated; Killer Cells, Natural; Leukemia; Lung Neoplasms; Lymphocyte Activation; Tissue Donors; Transplantation, Autologous; Transplantation, Homologous; Tumor Cells, Cultured | 1997 |
[Purging of hemopoietic progenitor cells in autologous transplantation].
Topics: Adult; Bone Marrow Purging; Child; Cyclophosphamide; Deferoxamine; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Methylprednisolone; Neuroblastoma; Transplantation, Autologous | 1997 |
Increased MRP expression is associated with resistance to radiation, anthracyclines and etoposide in cells treated with fractionated gamma-radiation.
Topics: Antibiotics, Antineoplastic; ATP-Binding Cassette Transporters; Dose Fractionation, Radiation; Drug Resistance; Etoposide; Gamma Rays; Humans; Leukemia; Multidrug Resistance-Associated Proteins; Radiation Tolerance; RNA, Messenger; Tumor Cells, Cultured | 1997 |
Mechanisms of resistance in a human cell line exposed to sequential topoisomerase poisoning.
Topics: Antineoplastic Agents; Camptothecin; Cell Nucleus; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Drug Resistance, Neoplasm; Etoposide; Humans; Leukemia; Phenotype; Point Mutation; RNA, Messenger; Tumor Cells, Cultured | 1997 |
Drug-induced death of leukaemic cells after G2/M arrest: higher order DNA fragmentation as an indicator of mechanism.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Cell Division; Cell Size; Coloring Agents; DNA Fragmentation; DNA, Neoplasm; Electrophoresis, Gel, Pulsed-Field; Etoposide; G2 Phase; Gene Expression; Humans; Leukemia; Mitosis; Polymerase Chain Reaction; Trypan Blue; Tumor Cells, Cultured | 1998 |
Bcr-Abl exerts its antiapoptotic effect against diverse apoptotic stimuli through blockage of mitochondrial release of cytochrome C and activation of caspase-3.
Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Caspase 3; Caspases; Cysteine Endopeptidases; Cytarabine; Cytochrome c Group; Enzyme Activation; Etoposide; Fusion Proteins, bcr-abl; Humans; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Promyelocytic, Acute; Membrane Potentials; Mitochondria; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species; Sphingolipids; Transfection; Tumor Cells, Cultured | 1998 |
Clinical approach to circumvention of multidrug resistance in refractory leukemic patients: association of cyclosporin A with etoposide.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blast Crisis; Child; Cyclosporine; Drug Resistance, Multiple; Etoposide; Female; Growth Inhibitors; Humans; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Tumor Cells, Cultured | 1997 |
Etoposide targets topoisomerase IIalpha and IIbeta in leukemic cells: isoform-specific cleavable complexes visualized and quantified in situ by a novel immunofluorescence technique.
Topics: Antigens, Neoplasm; Antineoplastic Agents, Phytogenic; DNA Topoisomerases, Type II; DNA-Binding Proteins; Dose-Response Relationship, Drug; Etoposide; Fluorescent Antibody Technique; Humans; In Situ Hybridization, Fluorescence; Isoenzymes; Leukemia; Tumor Cells, Cultured | 1998 |
Case 17: Essential thrombocythaemia with inversion 3 terminating in acute leukaemia.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Chromosome Inversion; Chromosomes, Human, Pair 3; Cytarabine; Etoposide; Fatal Outcome; Female; Humans; Karyotyping; Leukemia; Middle Aged; Mitoxantrone; Thrombocythemia, Essential | 1998 |
Graft rejection and recovery of host-derived hematopoiesis after allogeneic bone marrow transplantation: relation to conditioning with high dose etoposide and total body irradiation.
Topics: Acute Disease; Adult; Antineoplastic Agents, Phytogenic; Bone Marrow Transplantation; Etoposide; Graft Rejection; Hematopoiesis; Humans; Leukemia; Male; Transplantation, Homologous; Whole-Body Irradiation | 1998 |
The relationship between modulation of MDR and glutathione in MRP-overexpressing human leukemia cells.
Topics: Antineoplastic Agents; ATP-Binding Cassette Transporters; Buthionine Sulfoximine; Cell Division; Daunorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Gene Expression Regulation, Neoplastic; Genes, MDR; Glutathione; Humans; Leukemia; Multidrug Resistance-Associated Proteins; Tumor Cells, Cultured | 1998 |
Role of oxygen radicals generated by NADPH oxidase in apoptosis induced in human leukemia cells.
Topics: Alkaloids; Antineoplastic Agents, Phytogenic; Antioxidants; Apoptosis; Camptothecin; Catalase; Cell Differentiation; Cell Line; DNA Fragmentation; Enzyme Inhibitors; Etoposide; Flow Cytometry; Granulomatous Disease, Chronic; Humans; Hydrogen Peroxide; Leukemia; Membrane Glycoproteins; Monocytes; NADPH Oxidase 2; NADPH Oxidases; Neoplasm Proteins; Neutrophils; NF-kappa B; Pyrrolidines; Reactive Oxygen Species; Staurosporine; Thiocarbamates; Topoisomerase I Inhibitors; Tumor Cells, Cultured; Ultraviolet Rays | 1998 |
Signaling defect in the activation of caspase-3 and PKCdelta in human TUR leukemia cells is associated with resistance to apoptosis.
Topics: Apoptosis; Caspase 3; Caspases; Cytarabine; Enzyme Activation; Etoposide; Humans; Isoenzymes; Leukemia; Nucleic Acid Synthesis Inhibitors; Protein Kinase C; Protein Kinase C-delta; Signal Transduction; Tumor Cells, Cultured; U937 Cells | 1999 |
Secondary leukemia or myelodysplastic syndrome after treatment with epipodophyllotoxins.
Topics: Adolescent; Adult; Antineoplastic Agents, Phytogenic; Child; Child, Preschool; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Monitoring; Etoposide; Female; Follow-Up Studies; Humans; Infant; Leukemia; Male; Myelodysplastic Syndromes; Neoplasms, Second Primary; Risk Factors | 1999 |
Early detection by ultrasound scan of severe post-chemotherapy gut complications in patients with acute leukemia.
Topics: Acute Disease; Adult; Anti-Infective Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dilatation, Pathologic; Enterocolitis; Etoposide; Female; Gallbladder Diseases; Gastrointestinal Diseases; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Intubation, Gastrointestinal; Leukemia; Leukemia, Myelomonocytic, Acute; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neutropenia; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Treatment Outcome; Ultrasonography | 1999 |
Chemotherapy and donor peripheral blood progenitor cells for acute leukemia in early relapse after allogeneic bone marrow transplantation.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Etoposide; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Mitoxantrone; Recurrence; Time Factors; Tissue Donors; Transplantation Chimera; Transplantation, Homologous | 1999 |
Caspase-induced proteolysis of the cyclin-dependent kinase inhibitor p27Kip1 mediates its anti-apoptotic activity.
Topics: Amino Acid Chloromethyl Ketones; Apoptosis; Base Sequence; Calpain; Caspase 3; Caspase 6; Caspase 8; Caspase 9; Caspase Inhibitors; Caspases; CDC2-CDC28 Kinases; Cell Cycle Proteins; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase Inhibitor p27; Cyclin-Dependent Kinases; Cysteine Proteinase Inhibitors; Etoposide; Humans; Leukemia; Leupeptins; Microtubule-Associated Proteins; Molecular Sequence Data; Mutation; Nucleic Acid Synthesis Inhibitors; Oligopeptides; Protein Serine-Threonine Kinases; Thimerosal; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 1999 |
Pharmacokinetics of anticancer drugs in vitro.
Topics: Amino Acids; Antineoplastic Agents; Asparaginase; Cyclophosphamide; Cytarabine; Etoposide; HL-60 Cells; Humans; Leukemia; Tumor Cells, Cultured | 1999 |
[Mechanism of occurrence of secondary tumors by antitumor drugs].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; DNA Repair; DNA Topoisomerases, Type II; DNA-Binding Proteins; Doxorubicin; Etoposide; Histone-Lysine N-Methyltransferase; Humans; Leukemia; Myeloid-Lymphoid Leukemia Protein; Neoplasms, Second Primary; Proto-Oncogenes; Topoisomerase II Inhibitors; Transcription Factors; Translocation, Genetic | 1999 |
Treatment of normal and malignant cells with nucleoside analogues and etoposide enhances deoxycytidine kinase activity.
Topics: Antineoplastic Agents, Phytogenic; Child; Deoxycytidine Kinase; Enzyme Induction; Etoposide; Humans; Leukemia; Nucleosides; T-Lymphocytes | 1999 |
Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; California; Case-Control Studies; Cohort Studies; Combined Modality Therapy; Etoposide; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Leukemia, Radiation-Induced; Lymphoma; Male; Middle Aged; Multivariate Analysis; Myelodysplastic Syndromes; Neoplasms, Second Primary; Odds Ratio; Radiotherapy; Retrospective Studies; Risk Factors; Transplantation Conditioning; Treatment Outcome; Whole-Body Irradiation | 2000 |
Cell density-dependent VP-16 sensitivity of leukaemic cells is accompanied by the translocation of topoisomerase IIalpha from the nucleus to the cytoplasm.
Topics: Antineoplastic Agents, Phytogenic; Blotting, Western; Cell Nucleus; Cytoplasm; DNA Topoisomerases, Type I; Drug Resistance, Neoplasm; Etoposide; Flow Cytometry; Humans; Leukemia; Multiple Myeloma; Phenotype; Translocation, Genetic; Tumor Cells, Cultured | 2000 |
Serine palmitoyltransferase regulates de novo ceramide generation during etoposide-induced apoptosis.
Topics: Acyltransferases; Antineoplastic Agents, Phytogenic; Apoptosis; Biological Transport; Caspases; Ceramides; Enzyme Activation; Etoposide; Humans; Leukemia; Microsomes; Models, Biological; Mycotoxins; Oxidoreductases; Palmitates; Poly(ADP-ribose) Polymerases; Protease Inhibitors; Serine C-Palmitoyltransferase; Sphingosine; Trypan Blue; Tumor Cells, Cultured | 2000 |
Stochastic modeling of apoptosis tolerance distributions measured by multivariate flow analysis of human leukemia cells.
Topics: Apoptosis; Etoposide; Flow Cytometry; Humans; Intracellular Membranes; Leukemia; Light; Likelihood Functions; Linear Models; Membrane Lipids; Membrane Potentials; Mitochondria; Multivariate Analysis; Phosphatidylserines; Scattering, Radiation; Sensitivity and Specificity; Stochastic Processes; Tumor Cells, Cultured | 2000 |
Novobiocin-induced VP-16 accumulation and MRP expression in human leukemia and ovarian carcinoma cells.
Topics: Ascites; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette Transporters; Biological Transport; Bone Marrow; Etoposide; Female; Humans; Kinetics; Leukemia; Multidrug Resistance-Associated Proteins; Novobiocin; Ovarian Neoplasms; Tumor Cells, Cultured | 2000 |
E1A overcomes the apoptosis block in BCR-ABL+ leukemia cells and renders cells susceptible to induction of apoptosis by chemotherapeutic agents.
Topics: Adenovirus E1A Proteins; Antibiotics, Antineoplastic; Apoptosis; Blotting, Western; Caspase 3; Caspases; CDC2 Protein Kinase; Cell Cycle; Cell Division; Daunorubicin; DNA Damage; Dose-Response Relationship, Drug; Etoposide; Flow Cytometry; Fusion Proteins, bcr-abl; Humans; K562 Cells; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Luciferases; Microscopy, Phase-Contrast; Nucleic Acid Synthesis Inhibitors; Peptides; Plasmids; Poly(ADP-ribose) Polymerases; Transfection; Tumor Cells, Cultured | 2000 |
Antileukemic drugs increase death receptor 5 levels and enhance Apo-2L-induced apoptosis of human acute leukemia cells.
Topics: Acute Disease; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Apoptotic Protease-Activating Factor 1; BH3 Interacting Domain Death Agonist Protein; Carrier Proteins; Caspase 3; Caspase 8; Caspase 9; Caspases; Cytarabine; Cytochrome c Group; Doxorubicin; Etoposide; HL-60 Cells; Humans; Jurkat Cells; Leukemia; Membrane Glycoproteins; Proteins; Proto-Oncogene Proteins c-bcl-2; Receptors, TNF-Related Apoptosis-Inducing Ligand; Receptors, Tumor Necrosis Factor; TNF-Related Apoptosis-Inducing Ligand; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha; Tumor Suppressor Protein p53; U937 Cells; Up-Regulation | 2000 |
Down-regulation of bcr-abl and bcl-x(L) expression in a leukemia cell line and its doxorubicin-resistant variant by topoisomerase II inhibitors.
Topics: Amsacrine; Antineoplastic Agents; Apoptosis; bcl-X Protein; Chromatography, High Pressure Liquid; Down-Regulation; Doxorubicin; Drug Resistance, Neoplasm; Enzyme Inhibitors; Etoposide; Fusion Proteins, bcr-abl; Humans; K562 Cells; Leukemia; Proto-Oncogene Proteins c-abl; Proto-Oncogene Proteins c-bcl-2; Reverse Transcriptase Polymerase Chain Reaction; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 2000 |
Chemotherapy and marrow transplantation for congenital leukaemia.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Etoposide; Female; Humans; Infant, Newborn; Leukemia; Methotrexate; Mitoxantrone; Prednisolone; Treatment Outcome; Vincristine | 2001 |
Action of topoisomerase targeting drugs on non-Hodgkin's lymphoma and leukemia. Correlation of clinical and cell culture studies.
Topics: Acute Disease; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Cytarabine; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA-Binding Proteins; DNA, Neoplasm; Enzyme Inhibitors; Etoposide; Humans; Isoenzymes; Leukemia; Leukocytes; Lymphoma, Non-Hodgkin; Mitoxantrone; Polymerase Chain Reaction; RNA, Messenger; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan | 2000 |
Combination chemotherapy of intermediate-dose cytarabine, idarubicin, plus etoposide and subsequent mobilized donor leukocyte infusion for relapsed acute leukemia after allogeneic bone marrow transplantation.
Topics: Actuarial Analysis; Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cytarabine; Disease-Free Survival; Etoposide; Female; Graft vs Host Disease; Hematopoietic Stem Cell Mobilization; Humans; Idarubicin; Leukemia; Leukocyte Transfusion; Male; Recurrence; Survival Rate; Transplantation, Homologous | 2001 |
Respiratory chain-generated oxidative stress following treatment of leukemic blasts with DNA-damaging agents.
Topics: Apoptosis; Ceramides; Cytarabine; Digitonin; DNA Damage; Electron Transport; Electron Transport Complex III; Etoposide; Gamma Rays; Leukemia; Mitochondria; Nucleic Acid Synthesis Inhibitors; Oxidative Stress; Permeability; Reactive Oxygen Species; Thioredoxins; Tumor Cells, Cultured | 2001 |
Modulation of apoptosis by procaspase-2 short isoform: selective inhibition of chromatin condensation, apoptotic body formation and phosphatidylserine externalization.
Topics: Amino Acid Motifs; Apoptosis; Base Sequence; Caspase 2; Caspases; Chromatin; Cysteine; DNA Fragmentation; Enzyme Inhibitors; Enzyme Precursors; Etoposide; Humans; Isoenzymes; Leukemia; Molecular Sequence Data; Mutation; Phosphatidylserines; Topoisomerase II Inhibitors; Transfection; Tumor Cells, Cultured | 2001 |
Mitochondria-targeting drugs arsenic trioxide and lonidamine bypass the resistance of TPA-differentiated leukemic cells to apoptosis.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Caspases; Cell Differentiation; Cell-Free System; Drug Resistance; Etoposide; Humans; Indazoles; Leukemia; Mitochondria; Oxides; Proto-Oncogene Proteins c-bcl-2; Tetradecanoylphorbol Acetate; U937 Cells | 2001 |
Incidence of post transplant myelodysplasia/acute leukemia in non-Hodgkin's lymphoma patients compared with Hodgkin's disease patients undergoing autologous transplantation following cyclophosphamide, carmustine, and etoposide (CBV).
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Incidence; Leukemia; Lymphoma, Non-Hodgkin; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Transplantation, Autologous | 2001 |
Leukemia cutis in an elderly patient treated with low dose cytosine arabinoside and etoposide.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Etoposide; Exanthema; Humans; Immunophenotyping; Leukemia; Leukemia, Myeloid, Acute; Male | 2001 |
Quantitative determination of apoptosis on leukemia cells by infrared spectroscopy.
Topics: Apoptosis; Cell Count; Etoposide; Flow Cytometry; Leukemia; Spectrophotometry, Infrared; Tumor Cells, Cultured | 2001 |
Benzene metabolites antagonize etoposide-stabilized cleavable complexes of DNA topoisomerase IIalpha.
Topics: Antigens, Neoplasm; Antineoplastic Agents, Phytogenic; Benzene; Carcinogens; DNA; DNA Topoisomerases, Type II; DNA-Binding Proteins; Drug Antagonism; Drug Stability; Etoposide; Humans; Isoenzymes; Leukemia; Protein Binding; Topoisomerase II Inhibitors | 2001 |
Bax translocation is crucial for the sensitivity of leukaemic cells to etoposide-induced apoptosis.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Apoptotic Protease-Activating Factor 1; bcl-2-Associated X Protein; Biological Transport; Caspases; DNA Damage; Etoposide; Humans; K562 Cells; Leukemia; Proteins; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2 | 2001 |
Estimation of changes in vimentin filaments induced by etoposide and doxorubicin in human leukemia cell line K-562 by using immunofluorescence microscopy.
Topics: Antineoplastic Agents; Dose-Response Relationship, Drug; Doxorubicin; Etoposide; Humans; Intermediate Filaments; K562 Cells; Leukemia; Microscopy, Fluorescence; Vimentin | 2001 |
Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
Topics: Acute Disease; Adolescent; Adult; Busulfan; Child; Child, Preschool; Cyclophosphamide; Cyclosporine; Cytarabine; Disease-Free Survival; Etoposide; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Immunosuppressive Agents; Infant; Leukemia; Life Tables; Male; Methylprednisolone; Middle Aged; Premedication; Retrospective Studies; Risk; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Whole-Body Irradiation | 2002 |
Reduced DNA ligase activity in etoposide resistant human lymphatic leukaemia CEM cells.
Topics: Adenosine Monophosphate; Antineoplastic Agents, Phytogenic; Blotting, Western; DNA Ligase ATP; DNA Ligases; DNA Topoisomerases, Type II; Drug Resistance, Neoplasm; Etoposide; Humans; Leukemia; Tumor Cells, Cultured | 2002 |
Allogeneic BMT for infantile acute leukemia: what is the optimal conditioning regimen?
Topics: Acute Disease; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Disease-Free Survival; Etoposide; Growth Disorders; Humans; Infant; Leukemia; Radiation Injuries; Transplantation Conditioning; Transplantation, Homologous; Treatment Failure; Whole-Body Irradiation | 2002 |
Induction of apoptosis in human leukaemic cells by IPENSpm, a novel polyamine analogue and anti-metabolite.
Topics: Acetyltransferases; Antimetabolites; Apoptosis; Caspases; Dose-Response Relationship, Drug; Etoposide; HL-60 Cells; Humans; Leukemia; Nucleic Acid Synthesis Inhibitors; Polyamines; Time Factors; Tumor Cells, Cultured | 2002 |
The therapy of acute leukemia in the adult: a progress report.
Topics: Acute Disease; Adult; Antineoplastic Agents; Azacitidine; Blood Transfusion; Cytarabine; Daunorubicin; Dexamethasone; Etoposide; Granulocytes; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid; Patient Isolation; Platelet Transfusion; Pneumonia; Prednisone; Pyrimethamine; Remission, Spontaneous; Thioguanine; Vincristine; Zinostatin | 1976 |
[Myelomonocytoid leukemia, abnormal cellular clone with a marker chromosome, evolution with a possible cure].
Topics: Adult; Chromosomes, Human, 21-22 and Y; Clone Cells; Cytodiagnosis; Cytogenetics; Etoposide; Female; Humans; Leukemia; Leukemia, Myeloid | 1978 |
[Successful therapy of chronic myelomonocytic leukemia with vp 16-213 (author's transl)].
Topics: Age Factors; Aged; Chronic Disease; Etoposide; Granulocytes; Humans; Leukemia; Male; Monocytes; Podophyllotoxin | 1979 |
Rapid remission induction in adult acute non-lymphoblastic leukaemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Cytarabine; Doxorubicin; Drug Therapy, Combination; Etoposide; Female; Humans; Leukemia; Male; Middle Aged; Podophyllotoxin; Remission, Spontaneous; Sepsis; Time Factors | 1978 |
The measurement of nuclear topoisomerase II inhibition in vitro: a possible tool for detecting resistance on a subcellular level in haematopoietic malignancies.
Topics: Amsacrine; Antineoplastic Agents; Cell Nucleus; Drug Resistance; Etoposide; Humans; In Vitro Techniques; Leukemia; Leukemia, Promyelocytic, Acute; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 1992 |
Potentiation by novobiocin of the cytotoxic activity of etoposide (VP-16) and teniposide (VM-26).
Topics: Adenocarcinoma; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cell Survival; DNA; DNA Topoisomerases, Type II; Drug Synergism; Etoposide; Humans; Leukemia; Lung Neoplasms; Novobiocin; RNA; Teniposide; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 1992 |
Collection of peripheral blood stem cells mobilized by high-dose Ara-C plus VP-16 or aclarubicin followed by recombinant human granulocyte-colony stimulating factor.
Topics: Aclarubicin; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Cells; Blood Component Removal; Blood Transfusion, Autologous; Cytarabine; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Leukemia; Lymphoma; Male; Middle Aged; Recombinant Proteins | 1992 |
Low-dose etoposide: a potential therapy for myelodysplastic syndromes.
Topics: Acute Disease; Adult; Aged; Anemia, Refractory, with Excess of Blasts; Bone Marrow; Etoposide; Female; Humans; Leukemia; Male; Middle Aged; Myelodysplastic Syndromes | 1992 |
Bone marrow purging in patients with refractory cancer.
Topics: Adolescent; Adult; Bone Marrow Purging; Bone Marrow Transplantation; Breast Neoplasms; Child; Child, Preschool; Colony-Forming Units Assay; Etoposide; Female; Hematopoietic Stem Cells; Humans; In Vitro Techniques; Leukemia; Lymphoma; Male; Methylprednisolone; Middle Aged; Neoplasms; Transplantation, Autologous | 1992 |
New perspectives on the toxicity of etoposide.
Topics: Bone Marrow Diseases; Etoposide; Humans; Leukemia; Neoplasms, Second Primary; Podophyllotoxin | 1992 |
Allogeneic bone marrow transplantation for hematological malignancies following etoposide, cyclophosphamide, and fractionated total body irradiation.
Topics: Acute Disease; Adolescent; Adult; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cyclophosphamide; Drug Therapy, Combination; Etoposide; Female; Humans; Injections, Intravenous; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Transplantation, Homologous; Whole-Body Irradiation | 1992 |
Intracellular cytosine arabinoside accumulation and cytosine arabinoside triphosphate formation in leukemic blast cells is inhibited by etoposide and teniposide.
Topics: Acute Disease; Adult; Aged; Amsacrine; Arabinofuranosylcytosine Triphosphate; Cytarabine; Drug Interactions; Etoposide; Humans; Leukemia; Middle Aged; Neoplastic Stem Cells; Phosphorylation; Teniposide; Tumor Cells, Cultured | 1992 |
[Clinical application of enzyme inhibitors--hematologic malignancies].
Topics: Cytarabine; Deoxycytidine; DNA Topoisomerases, Type I; Etoposide; Gemcitabine; Humans; Leukemia; Mercaptopurine; Methotrexate; Purines; Pyrimidines; Thioguanine; Topoisomerase I Inhibitors | 1991 |
The effect of staurosporine on drug-induced, topoisomerase II-mediated DNA cleavage in human leukemia cells.
Topics: Alkaloids; Amsacrine; Cell Line; DNA Damage; DNA Topoisomerases, Type II; DNA, Neoplasm; Dose-Response Relationship, Drug; Drug Interactions; Etoposide; Humans; Leukemia; Protein Kinase C; Staurosporine; Tetradecanoylphorbol Acetate; Time Factors; Tumor Cells, Cultured | 1991 |
A combined approach for purging multidrug-resistant leukemic cell lines in bone marrow using a monoclonal antibody and chemotherapy.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bone Marrow; Bone Marrow Transplantation; Cell Separation; Chromium Radioisotopes; Complement System Proteins; Drug Resistance; Etoposide; Flow Cytometry; Hematopoietic Stem Cells; Humans; Leukemia; Membrane Glycoproteins; Tumor Cells, Cultured | 1991 |
Ablative therapy in bone marrow transplantation.
Topics: Bone Marrow Transplantation; Cyclophosphamide; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Lymphoma | 1991 |
[Intensive carboquone and cryopreserved autologous bone marrow transplantation for relapsed malignancies].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Transplantation; Carbazilquinone; Cisplatin; Combined Modality Therapy; Cryopreservation; Etoposide; Female; Hodgkin Disease; Humans; Leukemia; Male; Middle Aged; Nimustine | 1992 |
Improved results of allogeneic bone marrow transplantation for advanced hematologic malignancy using busulfan, cyclophosphamide and etoposide as cytoreductive and immunosuppressive therapy.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Busulfan; Child; Combined Modality Therapy; Cyclophosphamide; Drug Therapy, Combination; Etoposide; Graft vs Host Disease; Hepatic Veno-Occlusive Disease; Humans; Immunosuppressive Agents; Incidence; Leukemia; Middle Aged; Time Factors; Transplantation, Homologous | 1991 |
[Subleukemic acute monophagocytic leukemia. A biological phenotype close to malignant histiocytosis].
Topics: Aged; Aged, 80 and over; Aneuploidy; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Doxorubicin; Etoposide; Female; Giant Cells; Histiocytic Sarcoma; Humans; Leukemia; Leukemia, Myeloid; Phagocytosis; Thioguanine | 1991 |
Influence of immunosuppression on acute liver toxicity after intensified conditioning regimens for bone marrow transplantation in children.
Topics: Bone Marrow Transplantation; Busulfan; Child; Cyclosporins; Drug Therapy, Combination; Etoposide; Graft vs Host Disease; Humans; Immunosuppression Therapy; Leukemia; Liver; Lymphoma, Non-Hodgkin; Myelodysplastic Syndromes; Transplantation, Autologous; Whole-Body Irradiation | 1991 |
High-dose ara-C and etoposide in refractory or relapsing acute leukemia.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Evaluation; Etoposide; Female; Humans; Leukemia; Male; Middle Aged; Recurrence; Time Factors | 1991 |
Elimination of clonogenic tumor cells from bone marrow using methylprednisolone (MP) and etoposide VP16: an in vitro pharmacologic study.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Transplantation; Cell Death; Cell Separation; Dose-Response Relationship, Drug; Etoposide; Hematopoietic Stem Cells; Humans; Leukemia; Lymphoma; Methylprednisolone; Tumor Cells, Cultured | 1991 |
Differential in vitro sensitivity of human tumor and normal cells to chemotherapeutic agents and resistance modulators.
Topics: Adenocarcinoma; Antineoplastic Agents; Buthionine Sulfoximine; Cell Division; Cell Line; Cell Survival; Cisplatin; Cyclosporins; Doxorubicin; Drug Screening Assays, Antitumor; Etoposide; Humans; Kidney Neoplasms; Kinetics; Leukemia; Lymphocytes; Methionine Sulfoximine; Neurilemmoma; Tumor Cells, Cultured; Verapamil; Vincristine | 1991 |
Modulation of etoposide (VP-16) cytotoxicity by verapamil or cyclosporine in multidrug-resistant human leukemic cell lines and normal bone marrow.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cell Division; Cell Survival; Cyclosporins; Drug Resistance; Etoposide; Hematopoietic Stem Cells; Humans; Leukemia; Tumor Cells, Cultured; Verapamil | 1990 |
Treatment of relapsed or refractory acute leukemia: comparison of two different regimens.
Topics: Acute Disease; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Combined Modality Therapy; Cytarabine; Etoposide; Humans; Leukemia; Mitoxantrone; Neoplasm Recurrence, Local | 1990 |
High-dose etoposide and cyclophosphamide without bone marrow transplantation for resistant hematologic malignancy.
Topics: Acute Disease; Blood Cells; Bone Marrow Transplantation; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Resistance; Drug Therapy, Combination; Etoposide; Hodgkin Disease; Humans; Leukemia; Lymphoma; Spleen | 1990 |
In vitro cytotoxicity of VP-16-213 and nitrogen mustard: agonistic on tumor cells but not on normal human bone marrow progenitors.
Topics: Bone Marrow; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Etoposide; Hematopoietic Stem Cells; Humans; Leukemia; Lymphoma; Nitrogen Mustard Compounds; Tumor Cells, Cultured | 1990 |
Combined etoposide and 5-azacitidine in children and adolescents with refractory or relapsed acute nonlymphocytic leukemia: a Pediatric Oncology Group Study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Child; Drug Administration Schedule; Etoposide; Female; Humans; Leukemia; Male; Remission Induction; Time Factors | 1987 |
Effect of etoposide (VP16-213) on lipid peroxidation and antioxidant status in a high-dose radiochemotherapy regimen.
Topics: Anemia, Aplastic; Antioxidants; beta Carotene; Bone Marrow Transplantation; Carotenoids; Combined Modality Therapy; Etoposide; Humans; Leukemia; Lipid Peroxidation; Lipid Peroxides; Myelodysplastic Syndromes; Parenteral Nutrition; Radiotherapy Dosage; Time Factors; Vitamin E | 1989 |
Long-term endocrine toxicity of myeloablative treatment followed by autologous bone marrow/blood derived stem cell transplantation in patients with malignant lymphohematopoietic disorders.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cyclophosphamide; Endocrine System Diseases; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Libido; Lymphoma; Male; Menstruation Disturbances; Middle Aged; Ovarian Diseases; Whole-Body Irradiation | 1989 |
Multidrug resistance in cultured human leukemia and lymphoma cell lines detected by a monoclonal antibody, MRK16.
Topics: Antibodies, Monoclonal; ATP Binding Cassette Transporter, Subfamily B, Member 1; Dactinomycin; Daunorubicin; Doxorubicin; Drug Resistance; Etoposide; Gene Expression; Humans; Leukemia; Lymphoma; Membrane Glycoproteins; Mitoxantrone; RNA, Messenger; Tumor Cells, Cultured; Vinblastine; Vincristine; Vindesine | 1989 |
[Treatment of acute leukemia with "MB-triple V" therapy--a comparative study of "MB-triple V" therapy and B-triple V therapy].
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Evaluation; Etoposide; Female; Humans; Leukemia; Leukocyte Count; Male; Middle Aged; Mitoxantrone; Remission Induction; Vinblastine; Vincristine; Vindesine | 1989 |
New conditioning regimens for high risk marrow transplants.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cyclophosphamide; Cyclosporins; Drug Evaluation; Etoposide; Graft vs Host Disease; Humans; Leukemia; Lymphoma; Middle Aged | 1989 |
Characterization of resistance to VP-16 in human leukemic cell line.
Topics: Cell Line; DNA, Neoplasm; Drug Resistance; Etoposide; Humans; Leukemia; Tumor Cells, Cultured | 1989 |
Escalating doses of etoposide with cyclophosphamide and fractionated total body irradiation or busulfan as conditioning for bone marrow transplantation.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Child; Combined Modality Therapy; Cyclophosphamide; Etoposide; Graft vs Host Disease; Humans; Leukemia; Middle Aged; Whole-Body Irradiation | 1989 |
Treatment strategies in relation to drug action.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; DNA Topoisomerases, Type II; Etoposide; Hodgkin Disease; Humans; Leukemia; Lung Neoplasms; Lymphoma, Non-Hodgkin; Neoplasms; Podophyllotoxin; Teniposide | 1987 |
Acute nonlymphocytic leukemia following etoposide and cisplatin combination chemotherapy for advanced non-small-cell carcinoma of the lung.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Humans; Karyotyping; Leukemia; Lung Neoplasms; Male; Middle Aged | 1987 |
Etoposide-induced DNA cleavage in human leukemia cells.
Topics: Cell Division; Cell Line; DNA Damage; DNA Topoisomerases, Type II; DNA, Neoplasm; Etoposide; Humans; Immunologic Techniques; Interleukin-2; Leukemia; Lymphocyte Activation; Neoplasm Proteins; Tumor Cells, Cultured | 1987 |
Effect of 1-beta-D-arabinofuranosylcytosine (ara-C) on nuclear topoisomerase II activity and on the DNA cleavage and cytotoxicity produced by 4'-(9-acridinylamino)methanesulfon-m-anisidide (m-AMSA) and etoposide in m-AMSA-sensitive and -resistant human le
Topics: Amsacrine; Cell Division; Cell Nucleus; Cytarabine; DNA; DNA Topoisomerases, Type II; Drug Resistance; Etoposide; Humans; Leukemia; Tumor Cells, Cultured | 1987 |
Altered catalytic activity of and DNA cleavage by DNA topoisomerase II from human leukemic cells selected for resistance to VM-26.
Topics: Cell Cycle; Cell Division; Cell Line; Cell Nucleus; DNA Topoisomerases, Type II; Drug Resistance; Etoposide; Humans; Kinetics; Leukemia; Substrate Specificity; Tumor Cells, Cultured | 1988 |
Acute nonlymphocytic leukemia, preleukemia, and solid tumors following intensive chemotherapy of small cell carcinoma of the lung.
Topics: Acute Disease; Carcinoma, Small Cell; Chromosome Aberrations; Chromosome Disorders; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Etoposide; Female; Humans; Leukemia; Lomustine; Lung Neoplasms; Male; Methotrexate; Preleukemia; Risk; Vincristine | 1985 |
Membrane ordering effects of the anticancer agent VM-26.
Topics: 1,2-Dipalmitoylphosphatidylcholine; Animals; Carcinoma, Ehrlich Tumor; Cell Line; Cell Membrane; Cholesterol; Cyclic N-Oxides; Dimyristoylphosphatidylcholine; Electron Spin Resonance Spectroscopy; Etoposide; Humans; Leukemia; Lipid Bilayers; Liposomes; Male; Membrane Lipids; Mice; Podophyllotoxin; Spin Labels; Teniposide | 1986 |
Fractionated total body irradiation and high-dose VP 16-213 followed by allogeneic bone marrow transplantation in advanced leukemias.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Burkitt Lymphoma; Child; Combined Modality Therapy; Dose-Response Relationship, Drug; Etoposide; Graft vs Host Disease; Humans; Leukemia; Leukemia, Myeloid, Acute; Middle Aged; Prognosis; Whole-Body Irradiation | 1988 |
["A-Triple-V" treatment of relapsed or refractory acute leukemia].
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Evaluation; Etoposide; Female; Humans; Leukemia; Male; Middle Aged; Pilot Projects; Remission Induction; Vinblastine; Vincristine | 1988 |
Preclinical studies of the combination of mafosfamide (Asta-Z 7654) and etoposide (VP-16-213) for purging leukemic autologous marrow.
Topics: Antineoplastic Agents; Bone Marrow; Bone Marrow Transplantation; Cell Line; Cells, Cultured; Colony-Forming Units Assay; Cyclophosphamide; Etoposide; Humans; Leukemia; Lymphocyte Activation; Time Factors; Transplantation, Autologous | 1988 |
Combined chemotherapy with m-amsacrine in high-risk patients with acute non-lymphocytic leukemia.
Topics: Acute Disease; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Follow-Up Studies; Humans; Leukemia; Middle Aged; Thioguanine | 1987 |
High-dose ara-C and VP-16 before conditioning for bone marrow transplantation in patients with high-risk leukemia.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Cytarabine; Etoposide; Female; Humans; Leukemia; Male | 1987 |
Sequential pilot studies of intensive postremission chemotherapy for acute nonlymphocytic leukemia.
Topics: Acute Disease; Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Leukemia; Male; Middle Aged; Mitoxantrone; Pilot Projects; Thioguanine | 1987 |
VP-16-based regimen in adult acute nonlymphoblastic leukemia.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Erythropoiesis; Etoposide; Hematopoietic Stem Cells; Humans; Leukemia; Thioguanine; Vincristine | 1988 |
["B-triple V" therapy as a initial induction treatment of acute leukemias].
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Humans; Leukemia; Male; Middle Aged; Remission Induction; Vinblastine; Vincristine | 1987 |
A phase I-II study of cytosine arabinoside, daunorubicin, and VP16-213 in adult patients with acute non-lymphocytic leukemia.
Topics: Acute Disease; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Evaluation; Etoposide; Female; Humans; Leukemia; Male; Middle Aged; Nausea; Stomatitis; Vomiting | 1986 |
Phase I-II trial of VP-16 in the treatment of acute nonlymphocytic leukemia and blast crisis of chronic granulocytic leukemia.
Topics: Adult; Aged; Drug Administration Schedule; Drug Evaluation; Etoposide; Female; Hematologic Diseases; Humans; Leukemia; Leukemia, Myeloid; Male; Middle Aged; Stomatitis | 1986 |
[Phase II study of etoposide (VP-16) in the form of intravenous injection for malignant lymphomas and acute leukemias: Hanshin Cooperative Study Group for Hematological Disorders].
Topics: Adult; Aged; Drug Evaluation; Etoposide; Female; Hodgkin Disease; Humans; Injections, Intravenous; Leukemia; Leukemia, Myeloid, Acute; Lymphoma; Lymphoma, Non-Hodgkin; Male; Middle Aged | 1987 |
Idarubicin in combination with etoposide and cytarabine in adult untreated acute non lymphoblastic leukemia.
Topics: Acute Disease; Adolescent; Adult; Age Factors; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Idarubicin; Leukemia; Male; Middle Aged | 1987 |
Simple method for the administration of high-dose etoposide during autologous bone marrow transplantation.
Topics: Adult; Aged; Bone Marrow Transplantation; Drug Evaluation; Etoposide; Humans; Infusions, Parenteral; Leukemia; Lung Neoplasms; Middle Aged; Podophyllotoxin | 1986 |
Etoposide as an in vitro purging agent for the treatment of acute leukemias and lymphomas in conjunction with autologous bone marrow transplantation.
Topics: Bone Marrow; Bone Marrow Transplantation; Colony-Forming Units Assay; Etoposide; Hematopoietic Stem Cells; Humans; Leukemia; Lymphoma; Microscopy, Electron; Podophyllotoxin; Transplantation, Autologous | 1986 |
High-dose cyclophosphamide, BCNU, and etoposide followed by autologous bone marrow rescue as treatment for adult acute leukemia in relapse.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cyclophosphamide; Etoposide; Humans; Leukemia; Middle Aged; Recurrence; Transplantation, Autologous | 1986 |
Total body irradiation and high-dose etoposide: a new preparatory regimen for bone marrow transplantation in patients with advanced hematologic malignancies.
Topics: Acute Disease; Adult; Bone Marrow Transplantation; Child; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Evaluation; Etoposide; Graft vs Host Disease; Humans; Infant; Leukemia; Metabolic Clearance Rate; Whole-Body Irradiation | 1987 |
Evaluation of intensive postremission chemotherapy for adults with acute nonlymphocytic leukemia using high-dose cytosine arabinoside with L-asparaginase and amsacrine with etoposide.
Topics: Acute Disease; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cytarabine; Drug Evaluation; Etoposide; Humans; Leukemia; Middle Aged; Remission Induction; Statistics as Topic | 1987 |
[Pharmacological information. 8. Therapeutic agents for hemophilia and leukemia].
Topics: Etoposide; Hemophilia A; Humans; Leukemia; Vindesine | 1986 |
Phase II study of combination chemotherapy with etoposide and amsacrine in relapsed adult leukemia.
Topics: Adult; Aged; Aminoacridines; Amsacrine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Bone Marrow; Drug Evaluation; Etoposide; Humans; Leukemia; Middle Aged | 1986 |
[A new drug and current strategy in the treatment of acute non-lymphocytic leukemia in adults].
Topics: Acute Disease; Adult; Aminoacridines; Amsacrine; Anthraquinones; Antineoplastic Agents; Cytarabine; Drug Administration Schedule; Etoposide; Humans; Leukemia; Mitoxantrone | 1986 |
Drug sensitivity and cross-resistance of the 4'-(9-acridinylamino)methanesulfon-m-anisidide-resistant subline of HL-60 human leukemia.
Topics: Aminoacridines; Amsacrine; Cell Line; Cell Survival; Cytarabine; Doxorubicin; Drug Resistance; Etoposide; Humans; Leukemia | 1986 |
Preclinical assessment of purging with VP-16-213: key role for long-term marrow cultures.
Topics: Bone Marrow; Cells, Cultured; Colony-Forming Units Assay; Dose-Response Relationship, Drug; Etoposide; Hematopoietic Stem Cells; Humans; Leukemia; Lymphoma | 1987 |
Etoposide in combination with cytarabine, doxorubicin, and 6-thioguanine for treatment of acute nonlymphoblastic leukemia in a protocol adjusted for age.
Topics: Acute Disease; Adolescent; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Bone Marrow; Cytarabine; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Leukemia; Male; Middle Aged; Thioguanine | 1987 |
[A phase II trial of etoposide (VP-16) administered intravenously in the treatment of malignant lymphoma and acute leukemia].
Topics: Acute Disease; Adolescent; Adult; Aged; Drug Evaluation; Etoposide; Female; Humans; Infusions, Parenteral; Leukemia; Lymphoma; Male; Middle Aged; Podophyllotoxin | 1985 |
Phase I study of VP-16 (etoposide) and amsacrine (AMSA) in the treatment of refractory acute leukemia.
Topics: Acute Disease; Adult; Aged; Aminoacridines; Amsacrine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug Evaluation; Drug Resistance; Etoposide; Female; Humans; Leukemia; Liver Function Tests; Male; Middle Aged | 1985 |
Idarubicin alone or in combination with cytarabine and etoposide (3 + 3 + 5 protocol) in acute non-lymphoblastic leukaemia.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Idarubicin; Leukemia; Male; Middle Aged | 1985 |
Effects of antileukemic agents on the activity of terminal deoxynucleotidyl transferase from human normal thymic and leukemic cells "in vitro".
Topics: Adolescent; Antineoplastic Agents; Child; DNA Nucleotidylexotransferase; DNA Nucleotidyltransferases; Doxorubicin; Etoposide; Female; Humans; In Vitro Techniques; Infant; Kinetics; Leukemia; Lymphocytes; Male; T-Lymphocytes; Vincristine | 1985 |
[Phase II study of NK 171 (etoposide) on malignant lymphomas and acute leukemia. A cooperative study group on NK 171 in hematological malignancies].
Topics: Acute Disease; Adolescent; Adult; Aged; Alopecia; Anorexia; Drug Evaluation; Etoposide; Fatigue; Female; Humans; Leukemia; Lymphoma; Male; Middle Aged; Nausea; Podophyllotoxin | 1986 |
[Etoposide (VP 16/NK 171) and cytosine arabinoside combination chemotherapy in refractory childhood leukemia].
Topics: Acute Disease; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Drug Administration Schedule; Etoposide; Female; Humans; Infant; Leukemia; Lymphoma; Male; Myeloproliferative Disorders; Podophyllotoxin | 1986 |
Inhibition of 1-beta-D-arabinofuranosylcytosine transport and net accumulation by teniposide and etoposide in Ehrlich ascites cells and human leukemic blasts.
Topics: Animals; Binding Sites; Biological Transport; Carcinoma, Ehrlich Tumor; Cells, Cultured; Cytarabine; Etoposide; Humans; Leukemia; Male; Mice; Mice, Inbred Strains; Podophyllotoxin; Teniposide; Thioinosine; Tritium | 1985 |